MULTI-MODAL IMAGING OF TUMOR VASCULATURE AND TREATMENT RESPONSE IN PRECLINICAL CANCER MODELS by Cebulla, Jana
MULTI-MODAL IMAGING OF
TUMOR VASCULATURE AND
TREATMENT RESPONSE IN
PRECLINICAL CANCER 
MODELS
Thesis for the degree of Philosophiae Doctor
Trondheim, June 2015
Norwegian University of Science and Technology
Faculty of Medicine
Department of Circulation and Medical Imaging
Jana Cebulla
NTNU
Norwegian University of Science and Technology
Thesis for the degree of Philosophiae Doctor
Faculty of Medicine
Department of Circulation and Medical Imaging
© Jana Cebulla
ISBN 978-82-326-1004-4 (printed ver.)
ISBN 978-82-326-1005-1 (electronic ver.)
ISSN 1503-8181 
Doctoral theses at NTNU, 2015:174
Printed by NTNU Grafisk senter
 I 
 
Sammendrag 
Multimodal avbildning av tumorvaskulatur og behandlingsrespons i 
prekliniske modeller av kreft 
Kreft, en sykdom forårsaket av ukontrollert celledeling, forårsaker betydelig sykelighet 
og dødelighet i alle folkegrupper. Noen kreftpasienter har meget god prognose etter 
behandling med kirurgi, stråleterapi eller kjemoterapi, som utgjør bærebjelkene i dagens 
kreftbehandling. For andre pasienter er det dessverre vanskelig å oppnå et godt 
behandlingsresultat. Dette skyldes ulike faktorer som dårlige diagnostiske verktøy, 
inoperabilitet på grunn av tumorens størrelse og lokalisering, metastaserende kreftceller, 
behandlingsresistens eller dosebegrensende bivirkninger. Det er derfor et stort behov for 
nye behandlingstilbud for kreftpasienter.  
Mange nye legemidler rettet mot deregulerte signalveier i kreftceller er under klinisk 
utprøvning, og det blir ofte hevdet at denne typen legemidler kan bidra til effektiv, 
persontilpasset kreftbehandling. For å oppnå dette, trengs det nye metoder for å 
identifisere hvilke pasienter som vil ha utbytte av de ulike legemidler. Bedre metoder 
for å predikere behandlingsrespons krever at det utvikles og valideres biomarkører som 
kan brukes til å monitorere kreftutvikling og behandlingsrespons. Medisinsk avbildning 
kan potensielt brukes til å identifisere både responderende og behandlingsresistente 
pasienter tidlig i behandlingen, og dermed hjelpe til å skreddersy behandlingsopplegg 
for den enkelte kreftpasient. For å oppnå dette trengs det mer kunnskap om hvordan 
disse nye legemidlene påvirker fysiologiske egenskaper i tumorer.  
Angiogenese – dannelse av nye blodkar – er essensielt for tumorvekst og progresjon. 
Hemming av angiogenesen er derfor ansett som et attraktivt prinsipp for behandling av 
kreft. I tillegg har det vist seg at legemidler som hemmer signaloverføring i kreftceller, 
og dermed begrenser celledeling og tumorvekst, kan påvirke blodårenes funksjon. Økt 
forståelse av angiogenesen og hvordan nye legemidler kan påvirke vaskulær funksjon i 
tumorer kan derfor bidra til å øke behandlingseffekten i persontilpasset kreftbehandling. 
Hovedmålet i dette doktorgradsarbeidet var å evaluere hvordan ulike avbildnings-
modaliteter kan brukes til å vurdere morfologi og funksjon av blodkar i tumorer, og å 
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karakterisere cellulær og vaskulær respons på behandling med et legemiddel som 
hemmer kreftcellers signalveier. Avhandlingen består av tre artikler, hvor multimodal 
avbildning ble brukt i studier i xenograft-tumorer i mus.  
I den første artikkelen ble mikro-CT, mikro-MRI og in vivo MRI brukt til å studere 
vaskulatur i tumorer med ulik romlig oppløsning. Dette gjorde det mulig å sammenligne 
ulike teknikker for å estimere blodvolum i tumorer, og dermed bekrefte nøyaktigheten 
av blodvolumestimater basert på in vivo MRI. I den andre artikkelen ble effekten av 
PI3K-hemmeren BEZ235 evaluert i to forskjellige xenograft-modeller av eggstokkreft 
ved hjelp av in vivo MRI, mikro-CT og histopatologiske metoder. Vi fant at en krefttype 
med høy aktivitet i PI3K-signalveien responderte godt på behandlingen mens en 
krefttype med lav aktivitet responderte dårlig. I tillegg fant vi at MRI-markører for 
celletetthet og histopatologiske markører for proliferasjon hadde bedre prediktive 
egenskaper enn MRI- og CT-baserte markører for vaskulære endringer. I den tredje 
artikkelen kombinerte vi dynamisk in vivo MRI og intravital mikroskopi for å kunne 
studere opptaket av nanopartikler i xenograftede eggstokkreft-tumorer. Her fant vi at 
denne fremgangsmåten var godt egnet til å studere dynamikken i nanopartikkel-opptaket 
i tumorene in vivo, noe som kan være av betydning i forståelsen av hvordan 
nanopartikler kan brukes til målrettet levering av legemidler til en tumor.  
Samlet utgjør disse tre artiklene en helhet, der en rekke forskjellige bruksområder for 
multimodal avbildning i prekliniske kreftmodeller blir presentert og evaluert. 
Resultatene i avhandlingen bidrar til utvikling innenfor preklinisk kreftforskning 
gjennom økt forståelse av hvordan medisinske avbildningsteknikker gjenspeiler 
fysiologiske forhold i tumorer. Funnene i avhandlingen kan også bidra til mer rasjonell 
bruk av MR-avbildning i klinisk, persontilpasset kreftbehandling.  
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Summary 
Multi-modal imaging of tumor vasculature and treatment response in 
preclinical cancer models 
Cancer, a disease characterized by uncontrolled cell growth, causes significant 
morbidity and mortality across the world. Some cancers can successfully be treated with 
the standard therapies – surgery, radiotherapy or chemotherapy. However, many types 
of cancer are challenging to treat because of various factors such as poor diagnostic 
procedures, inoperability due to tumor location, formation of metastases, treatment 
resistance, and dose-limiting side effects of therapies. Therefore, improved treatment 
strategies are urgently needed.  
New drugs targeting the dysregulated signaling pathways in cancer are being tested in 
clinical trials, and it is frequently suggested that these drugs can contribute to 
personalized treatment of cancer. To achieve this, novel methods for identifying the 
right drugs for the right patients are required. Improved prediction of treatment response 
requires development and validation of biomarkers that can monitor cancer 
development and treatment response. Using medical imaging to identify treatment 
responders or non-responders at early time points can therefore contribute to improved 
tailoring of therapy to individual cancer patients. To achieve this, we need to understand 
how these targeted drugs affect tumor physiology.  
Angiogenesis, the formation of new blood vessels, which is essential for tumor growth 
and progression, is an attractive therapeutic target. Furthermore, drugs targeting 
signaling pathways that drive cellular proliferation have also been reported to interfere 
with the vascular function in tumors. A better understanding of angiogenic processes 
and vascular changes resulting from targeted cancer treatment is therefore needed. 
 The main objective of this thesis was to evaluate different imaging modalities in their 
ability to assess tumor vascular morphology and function, and to characterize cellular 
and vascular response to targeted treatment. The thesis consists of three papers, in 
which multi-modal imaging was performed on cancer xenografts grown in mice.  
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In the first paper, high resolution micro-CT, micro-MRI and in vivo MRI were 
combined to examine the vasculature of breast tumor xenografts at multiple spatial 
scales. The use of multi-modal imaging allowed the validation of in vivo MRI 
biomarkers of blood volume.  
In the second paper, tumor response to BEZ235, a drug inhibiting the PI3-kinase 
pathway, was studied in two ovarian xenograft types with in vivo MRI, micro-CT and 
histology. We found that the xenograft type with upregulated PI3-kinase activity 
responded strongly to the treatment while the type with lower PI3-kinase activity did 
not. In addition, we found that MRI biomarkers of cell density and histological markers 
of cell proliferation were better indicators for response to this treatment than MRI and 
CT biomarkers of vascular change.  
In the third paper, we combined dynamic in vivo MRI and intravital microscopy to 
quantify uptake of nanoparticles in ovarian tumor xenografts. It was found that this 
approach may be well suited to study nanoparticle dynamics on the whole tumor level 
in vivo, which is of importance e.g. for  the use of nanoparticles as drug carriers. 
Collectively, this thesis presents a wide spectrum of possible applications of multi-
modal imaging for preclinical cancer research. Also, the potential utility of in vivo MRI 
biomarkers in clinical cancer imaging is discussed. The results of this thesis therefore 
contribute to advancing preclinical cancer research, but also to clinical implementation 
of multimodal MR imaging in cancer.  
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Symbols and abbreviations 
|Į >  low energy spin state 
Įvȕ3  Alpha-v beta-3 integrin 
|ȕ>  high energy spin state 
1H  hydrogen 
ADC  apparent diffusion coefficient 
AIF  arterial input function 
Akt  Protein kinase B 
B0  external magnetic field strength 
B1  temporarily applied magnetic field strength 
C  contrast agent concentration 
CT  computed tomography 
į   diffusion gradient duration 
ǻ   time between two diffusion gradients 
ǻE  energy difference 
ǻȤ   susceptibility difference between blood with and without contrast agent 
DAPI  4',6-diamidino-2-phenylindole 
DCE  dynamic contrast enhanced 
DW  diffusion weighted 
E  energy 
EES  extracellular, extravascular space 
Ef  extraction fraction 
EPR  enhanced permeability and retention 
F   blood flow per unit mass of tissue 
G  gradient strength 
Ȗ  gyromagnetic ratio 
Gd  Gadolinium 
Gd-DTPA Gadopentetic acid 
ʄ  reduced Plack constant 
Hct  blood hematocrit 
HES  hematoxylin, eosin, saffron 
HIF-1Į hypoxia-inducible factor 1  
HUVEC human umbilical vein endothelial cells  
I  X-ray intensity 
i.v.  intraveneous 
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IVM  intravital microscopy 
k  Boltzmann constant 
kep  rate constant between EES and blood plasma 
Ki   transfer constant from plasma to EES 
Ktrans   volume transfer constant between blood plasma and EES 
M  magnetization 
MRI   magnetic resonance imaging 
mTORC1 mammalian target of ramapycin complex 1  
mTORC2 mammalian target of ramapycin complex 2 
  magnetic moment (chapter 1.2) 
X-ray attenuation coefficient (chapter 1.3) 
CT  micro-computed tomography 
MRI  magnetic resonance microscopy 
N  population of spin states 
NMR   nuclear magnetic resonance 
NO  nitric oxide 
NOS  nitric oxide synthase 
Ȧ0  Larmor frequency 
p-  phosphorylated 
PDK1  3-phosphoinositide dependent kinase-1 
PET   positron emission tomography 
PI3K  phosphatidylinositol 3-kinase 
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha  
PIP2  phosphatidylinositol-4,5-bisphosphate 
PIP3  phosphatidyl-inositol-3,4,5-triphosphate 
PSA  prostate specific antigen 
PTEN  phosphatase and tensin homolog 
R1  longitudinal relaxation rate 
R2  transverse relaxation rate 
r1,2  relaxivity 
RARE  rapid acquisition with refocused echoes 
RECIST Response Evaluation Criteria in Solid Tumors 
rf  radio frequency 
RGD  Arginylglycylaspartic acid (Arg-Gly-Asp) 
ȡp  proton density 
ȡt  tissue density 
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RTK  receptor tyrosine kinase 
S  signal intensity 
SCID  severe combined immunodeficiency 
SPECT  single photon emission computed tomography  
SSC  steady state susceptibility contrast 
STI  signal transduction inhibitor 
T  temperature 
T1  longitudinal relaxation time 
T2  transverse relaxation time 
TE  echo time 
TR  repetition time 
ve   volume of EES per unit volume of tissue 
VEGF  vascular endothelial growth factor 
VIF  vascular input function 
vp  blood plasma volume per unit volume of tissue 
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1 Introduction 
1.1 Cancer 
Cancer is a large group of complex and heterogeneous diseases, characterized by 
uncontrolled cell division and the potential to invade other tissues and spread to distant 
sites, a process called metastasis [1,2]. There exist more than 100 types of cancer [2,3], 
but there are certain characteristics that are thought to be acquired by all cancer cells to 
empower their survival, proliferation and spread [4]. In 2000, Hanahan and Weinberg 
termed these traits the “hallmarks of cancer” and listed them as “sustaining proliferative 
signaling”, “evading growth suppressors”, “activating invasion and metastasis”, 
“enabling replicative immortality”, “inducing angiogenesis” and “resisting cell death” 
[3]. About 10 years later, this list was revised and “deregulating cellular energetics” and 
“avoiding immune destruction” were added as “emerging hallmarks” [4]. In addition, 
two “enabling characteristics” – “genome instability and mutation” and “tumor 
promoting inflammation” – were discussed [4].  
Its complexity and heterogeneity make cancer difficult to treat. Cancer is one of the 
leading causes of death with 8.2 million cancer deaths and 14.1 million new cancer 
cases in 2012 worldwide [5]. While the age-standardized incidence rate of cancer has 
mostly been stable or rising, the mortality rates have been decreasing over the past 20 
years [5], which may be attributed to the improved cancer detection and treatment 
options available to us today. Best treatment outcome is achieved when the cancer is 
detected early, before it has metastasized. The current treatment options are surgery, 
radiotherapy, chemotherapy and new targeted therapies.  
 
1.1.1 Breast Cancer 
Breast cancer is the most frequent type of cancer diagnosed in women and is the second 
leading cause of cancer mortality in women in developed countries after lung cancer [5]. 
Most breast cancer patients receive breast conserving surgery or mastectomy, often with 
adjuvant radio- or chemotherapy and, in some cases, supported by targeted therapies 
[6]. Especially patients with late-stage breast cancer receive chemotherapy with or 
without other therapies [6]. In Norway and the USA, the overall 5-year survival rate is 
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about 89%, which is relatively high, but for patients with distant metastases (about 5%), 
the 5-year survival rate is dramatically reduced to about 26% [7,8]. In addition, the most 
aggressive breast cancer types are often found in women below 50 [8]. The high 
incidence of breast cancer and the high mortality rates of mostly younger women with 
aggressive subtypes of the disease have propelled large investments in breast cancer 
research.  
 
1.1.2 Ovarian Cancer 
Ovarian cancer is the most lethal form of gynecological cancer because most cases are 
diagnosed when the cancer has already metastasized. The overall five-year survival rate 
is only about 45% [8,9]. The standard treatment for ovarian cancer is cytoreductive 
surgery and platinum-based chemotherapy combined with taxane or, more recently, 
liposomal doxorubicin [10]. Most patients respond well to first-line therapy; however, 
the median progression-free survival is only 18 months [11], and the patients often 
relapse with chemotherapy-resistant cancer [10]. For over 30 years, the treatment has 
not changed much [10] and accordingly, the 5-year survival rates have only slightly 
increased [8,10]. Hence, new therapeutic approaches such as targeted therapies are 
urgently needed to improve patient survival [10,12].  
 
1.1.3 Targeted cancer treatment  
While conventional chemotherapy is cytotoxic to all rapidly diving cells, targeted 
therapies are more specifically directed at cancer cells by interfering with molecules 
directly linked to the cancer cells’ proliferation and survival with less side effects on 
healthy tissue [13]. Targeted cancer therapies are a form of precision medicine, where 
the patient’s genetic or protein expression profile is analyzed for abnormal activity to 
identify potential therapeutic targets and to develop a treatment plan. Targeted therapies 
include hormone therapy, signal transduction inhibitors (STIs), angiogenesis inhibitors 
and others [13]. 
Although research has provided remarkable advances in knowledge about the hallmarks 
of cancer and the biological mechanisms that cancer cells utilize in their favor, the large 
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network of interacting pathways is so complex that we still cannot reliably predict if a 
cancer will respond to treatment. In addition, cancers often develop resistance to 
targeted treatments through mutation or circumvention of a specific pathway by relying 
on other pathways instead [4,13]. These adaptive mechanisms are not yet understood 
sufficiently, and unfortunately, resistance often limits long-term disease control.  
 
1.1.4 Tumor vasculature and angiogenesis 
Angiogenesis is the formation of blood vessels from pre-existing vasculature. It is 
required for cancers to grow beyond a size of about 2-3 mm and satisfy their need for 
oxygen and nutrients [14]. Angiogenesis is listed as one on the hallmarks of cancer [3] 
as it is essential for cancer growth, invasion and metastasis [15]. 
Pro- and anti-angiogenic molecules regulate the growth of new blood vessels and are 
usually balanced in normal tissue. Certain triggers, however, can disturb this balance in 
the favor of pro-angiogenic molecules. These can be produced e.g. by cancer cells, 
endothelial cells or fibroblasts. Perhaps the best characterized trigger for the production 
of pro-angiogenic molecules is hypoxia, but also other factors like pH, mechanical 
stress, inflammatory response and genetic alterations can influence their production 
[16]. Hypoxia arises when the nearest functional blood vessel is too far away to deliver 
sufficient oxygen to the tumor cells [16]. A low intracellular oxygen concentration 
induces the expression and activation of the Į subunit of hypoxia-inducible factor 1 
(HIF-1Į) [17]. This, in turn, leads to the production of vascular endothelial growth 
factor (VEGF), which, among other factors, promotes the growth of new blood vessels 
[17,18].  
The overproduction of pro-angiogenic factors causes the tumor vasculature to be 
abnormal both in morphology and function [19]. Compared to normal blood vessels, 
tumor vessels are disorganized, tortuous, often dilated, with numerous branches, 
arteriovenous shunts or blind ends [16] (Fig. 1). Some areas in a tumor can be highly 
vascularized while other areas contain only few vessels [19]. In addition, tumor 
vasculature is hyperpermeable to macromolecules [20], which causes high interstitial 
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fluid pressure [19]. These traits lead to a poorly functioning tumor vasculature with 
turbulent blood flow and poor perfusion, which may lead to vessel collapse [19].  
 
Figure 1: Normal blood vessels (left) versus tumor blood vessels (right). Normal vessels form 
highly organized capillary beds which are well suited for the delivery of oxygen and nutrients to 
the tissue. Tumor vessels are disorganized with large, tortuous vessels, blind ends and frequent 
branching, which may lead to poor perfusion and collapse of non-functional vessels.  
These vascular abnormalities do not seem to be a disadvantage for the tumor but may 
even contribute to greater malignancy. Vascular function is also of great importance for 
traditional cancer therapy [19]. Dysfunctional vasculature makes the delivery of 
chemotherapeutics to the tumor challenging and low oxygen levels can reduce the 
efficacy of radiation therapy [19]. 
 
1.1.5 Anti-angiogenic therapy 
In 1971, Judah Folkman was the first to suggest “anti-angiogenic” therapy as a new 
mode of cancer treatment. Today, there are several clinically approved drugs that 
directly or indirectly target angiogenesis, and many more are in development. The first 
and most widely used VEGF inhibitor is bevacizumab, which today is approved for the 
treatment of several types of cancer [21], e.g. in combination with chemotherapy for 
metastatic colorectal cancer, renal cancer and platinum resistant and reoccurring 
epithelial ovarian cancer [22,23]. Despite high expectations for its anti-cancer efficacy, 
only modest benefits have been demonstrated as many clinical studies fail to report 
improvements in overall survival [21]. One major problem associated with the limited 
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effects of anti-angiogenic therapy is an intrinsic or acquired resistance to the drugs, 
which can be caused e.g. through the activation of alternative signaling pathways [24]. 
This may even lead to the development of more aggressive cancer with increased 
metastatic potential [21].   
A large number of clinical trials are still being conducted to gather more data on the 
efficacy of anti-angiogenic agents in various types of cancer, mostly as combination-
therapy and also as adjuvant or neoadjuvant therapeutics [21]. However, to tackle the 
biggest challenge of predicting drug efficacy under various conditions such as cancer 
type, stage and drug combinations, it will be necessary to conduct more preclinical 
studies to better understand how these drugs affect the tumors and their vasculature and 
what factors lead to further tumor progression. Especially the use of more relevant 
preclinical cancer models will be important [21].  
 
1.1.6 Įvȕ3 integrin 
Alpha-v beta-3 (Įvȕ3) integrin expression is upregulated in some cancer cells and is also 
highly expressed on the surface of tumor endothelial cells, facilitating their migration 
and thereby influencing tumor angiogenesis [25]. Integrins are a family of 
transmembrane receptors consisting of one Į and one ȕ subunit. They are mediators of 
cell-cell adhesion and cell adhesion to extracellular matrix proteins [26] and thus play 
important roles in cell spreading and migration [16]. Integrins can also activate various 
signaling pathways [26].  
 Integrin Įvȕ3 belongs to a subgroup of integrins that recognize proteins containing the 
amino-acid sequence Arg-Gly-Asp (RGD) through which it binds certain extracellular 
matrix proteins such as fibronectin and vitronectin [26,27]. The expression of Įvȕ3 is 
stimulated by several angiogenic growth factors and its availability on the cell surface is 
regulated by a dynamic process of endocytotic recycling, in which the integrin is 
internalized into the cell via endocytosis and recycled back to the cell surface without 
degradation [28]. This receptor recycling has been found to happen via two different 
mechanisms that require about 3 and 10 minutes, respectively, for half of the integrins 
to perform one recycling loop [28]. 
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The upregulation of Įvȕ3 on angiogenic tumor vasculature has motivated the 
development of cilengitide, an inhibitor of Įvȕ3 and Įvȕ5, but so far it has not shown 
substantial clinical anticancer treatment effects [29]. A better understanding of 
processes involving Įvȕ3 functionality and targeting is therefore necessary. Especially 
non-invasive preclinical visualization and quantification methods for in vivo integrin 
expression and dynamics may be essential [30]. For this purpose, various compounds 
containing the RGD peptide for Įvȕ3 targeting properties have been produced, for 
example with radioactive properties for PET imaging, fluorescent properties for optical 
imaging, or paramagnetic properties for magnetic resonance imaging [30]. 
 
1.1.7 PI3K pathway in cancer 
One signal transduction pathway often upregulated in cancer is the phosphatidylinositol 
3-kinase (PI3K) pathway, which is an important regulator of cellular functions such as 
growth, proliferation, apoptosis and metabolism [31].  
PI3Ks are a family of intracellular lipid kinases that phosphorylate the 3´-hydroxyl 
group of phosphatidylinositol and phosphoinositides (i.e. the phosphorylated forms of 
phosphatidylinositol). There are three classes of PI3Ks, grouped according to their 
structure and substrate preference [32]. The class I PI3Ks can be activated by growth 
factor receptor tyrosine kinases (RTKs) or G-protein-coupled receptors as illustrated in 
Fig 2. 
In response to extracellular signals, Class I PI3K primarily catalyzes the 
phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidyl-
inositol-3,4,5-triphosphate (PIP3). This process is directly opposed by the phosphatase 
and tensin homolog (PTEN), which negatively regulates the pathway activity [31]. PIP3 
can recruit and bind the serine-threonin kinase AKT, which can be activated by 
phosphorylation at threonine 308 by 3-phosphoinositide dependent kinase-1 (PDK1) 
and at serine 473 by the rapamycin-insensitive mammalian target of ramapycin complex 
(mTORC2) [31,33]. Phosphorylated AKT (p-AKT) is of central importance for the 
regulation of numerous biological processes [34]. For instance, p-AKT leads to the 
activation of the rapamycin-sensitive mTOR complex (mTORC1). This complex 
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activates p70S6 kinase, which, in turn, phosphorylates S6 ribosomal protein and 
ultimately increases protein synthesis [35,36]. 
 
Figure 2: Schematic illustration of the PI3K signaling pathway as explained in the text. Note that 
this is a simplified and incomplete representation of the pathway. Figure based on [31-39]. 
Angiogenesis is thought to be mainly induced by hypoxia, but also the PI3K pathway 
has a role in the regulation of angiogenesis [37]. In recent years it was shown that HIF-1 
activity is influenced by PI3K pathway activity in cancer cells, which results in the 
expression of VEGF [17,37,38]. Furthermore, phosphorylation of AKT can lead to 
activation of nitric oxide synthase (NOS), which can induce angiogenesis by producing 
nitric oxide (NO) [39].  
Important effectors found to be dysregulated in cancer include phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA); PTEN; and Akt [32]. Since 
the PI3K pathway is so important for cancer development, drugs inhibiting PI3K, Akt or 
mTOR have been developed and are currently undergoing clinical trials [37,38].  
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1.1.8 Biomarkers for therapy stratification and treatment response  
In cancer patients, a treatment plan is usually established after evaluation of tumor type, 
location and size, as well as histopathological and molecular analyses. However, it is 
difficult to reliably predict drug treatment response using genetic information [40]. 
Furthermore, the development of drug resistance is difficult to predict. Therefore, 
response is usually evaluated after treatment onset by measuring tumor size according to 
the RECIST guidelines, which are the ‘Response Evaluation Criteria in Solid Tumors’ 
[41]. For some cancers, also blood-based markers can be used for cancer detection and 
assessment of treatment response. For example, elevated prostate specific antigen (PSA) 
can indicate prostate cancer [42], while CA 125 is a serum protein often elevated in 
ovarian cancer patients [43]. Unfortunately, these blood-based biomarkers have limited 
predictive value [42,44], especially when they are assessed early during treatment [45]. 
Also tumor volume-based response assessment is not always optimal since volume 
decrease may occur slowly, and especially for molecularly targeted drugs, response is 
often associated with functional (e.g. vascular or cytological) rather than volumetric 
changes [46-48]. This highlights a need for novel non-invasive biomarkers for 
assessment of early response in order to enable prompt detection of therapeutic 
resistance and timely adjustment of treatment strategies for non-responders. This is 
important especially for the patients, as it will minimize unnecessary side effects from 
ineffective treatment. In addition, better customization of treatment can help to reduce 
costs for drugs and other healthcare services. Functional imaging biomarkers are now 
being investigated for early assessment of treatment-induced changes in tumor 
cellularity, vascularization or metabolic activity [47].  
 
1.1.9 Tumor microenvironment 
To understand the complex biology of tumors, one needs to look at tumor cells in their 
microenvironment, which consists of cells, vasculature and interstitium, also called the 
extracellular, extravascular space (EES) [49].  
The cellular component of tumors is composed of cancer cells, cancer stem cells and 
non-cancerous cells, among which are immune inflammatory cells, fibroblasts, 
endothelial cells and pericytes [4]. The latter two make up the blood vessels, which 
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supply the tumor with oxygen and nutrients. The EES is made up of the extracellular 
matrix, a hydrophilic gel consisting of interstitial fluid, macromolecules and collagen 
fibers. The interstitial fluid pressure is characteristically elevated in tumors, increases 
towards the tumor core, and is higher for large tumors [49]. 
A complex network of interactions between the cancer cells and their microenvironment 
is formed as the tumor progresses and is the basis for the development of high-grade 
malignant tumors with metastatic potential [4].   
 
1.1.10 Animal models of cancer 
Cancer cell lines are an important tool for the in vitro characterization of gene 
expression, signaling pathways or metabolism on a cellular level. However, in vitro 
experiments of drug sensitivity have been shown to be strongly dependent on the study 
design [50]. In addition, the tumor microenvironment plays an important role in cancer 
development [4]. For instance, while endothelial cells can be grown in vitro to study 
their cellular characteristics, the full complexity of tumor angiogenesis can only be 
recapitulated in vivo, where the entire microenvironment is involved in the induction of 
blood vessel growth. Therefore, the use of suitable preclinical cancer models is a 
necessary step for the in-depth characterization of cancer as a biological system, the 
study of treatment response or resistance, and the establishment of new biomarkers for 
cancer detection and treatment response. Especially for the development of new drugs, 
animal testing is required before drugs can be tested in a clinical setting [51].  
In preclinical research, tumors either develop spontaneously in transgenic animals, are 
induced by e.g. carcinogens, or are grown from xenografts of cancer cells or cancer 
tissue from patients. Xenografts are frequently used for medical imaging studies 
because they grow relatively quickly and are easy to use [52]. The growth of xenografts 
grown from human cancer cells or tissue requires immunodeficient mice such as severe 
combined immunodeficiency (SCID) mice or mice with a Foxn1nu mutation that have 
an abnormal thymus and lack fur (nude). Tumor xenografts grown from cell lines 
cannot perfectly model human cancer because of differences in the initiation of the 
tumor development, metastasis formation and the tumor microenvironment, e.g. due to 
the lack of immune cells and a homogeneous cancer cell population [53]. In addition, 
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drug response in clinical trials is often lower than expected from results in tumor 
xenografts [54]. Nevertheless, subcutaneous xenografts grown from tumor cell lines 
have provided relevant information to the clinic [55] and many cell lines are very well 
characterized and commercially available, which can make the comparison of studies 
using the same cell lines easier. Therefore, xenografts are still frequently used in 
preclinical research and are helpful tools for developing tumor or vascular imaging 
methods and biomarkers.  
 
1.1.11 Medical imaging in cancer 
Since the introduction of the X-ray, medical imaging has increasingly contributed to the 
diagnosis and follow-up of cancer patients. Today, medical imaging is increasingly 
being used in all stages of the disease for prediction, screening, staging, prognosis, 
therapy planning, response, recurrence and palliation [56]. The imaging modalities 
available today are based on different physical principles and therefore vary greatly in 
resolution, contrast and sensitivity. For example, X-ray and computed tomography (CT) 
rely on the attenuation of X-rays in the body, positron emission tomography (PET) and 
single photon emission computed tomography (SPECT) detect the distribution of 
radioactive tracers in the body, magnetic resonance imaging (MRI) uses low frequency 
microwaves and strong magnetic fields to create images of various contrasts, and 
ultrasound uses acoustic waves and their reflection to image different tissue structures. 
The choice of imaging modalities depends on the application, e.g. screening for breast 
cancer is performed by X-ray mammography (mostly due to lower costs and higher 
availability), while MRI is better suited for diagnosing and monitoring cancer due to 
better resolution and various available image contrast techniques. The use of multi-
modal imaging in cancer is increasing due to the complementary information available 
from different imaging techniques and dual imaging systems such as PET/CT or 
PET/MR have been developed for this purpose.  
In the following chapters, the imaging modalities used for this thesis are described in 
more detail.    
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1.2. Magnetic resonance imaging 
Magnetic resonance imaging (MRI) is based on the principles of nuclear magnetic 
resonance, which were first described by Rabi in 1938 [57] and for which he earned the 
Nobel Prize in Physics in 1944. This was followed by another Nobel Prize in 1952 for 
Bloch and Purcell who measured nuclear magnetic resonance (NMR) signals in water 
and paraffin [58,59]. But it was not until 1973 that Lauterbur [60] and Mansfield [61] 
described how NMR can be used to create images for which they were awarded the 
Nobel Prize in Physiology or Medicine in 2003.  
Today, MRI is a well-established medical imaging method that is very versatile as it is 
sensitive to a wide array of tissue properties and provides unique soft tissue contrast. 
This makes MRI a powerful technique to study diseases including cancer. Moreover, 
MRI is non-invasive and does not involve ionizing radiation, which is highly beneficial 
when a repeated assessment of disease progression and treatment response is required.  
The physics behind MRI is rather complex, so here, only certain basic and simplified 
principles will be discussed. A more comprehensive explanation of NMR can be found 
in [62] and a description from MRI basics to advanced imaging techniques can be found 
e.g. in [63].  
 
1.2.1 Basics of nuclear magnetic resonance 
NMR is based on the intrinsic property of atomic nuclei to possess a spin, which can be 
systematically manipulated with external magnetic fields. The nuclear spin depends on 
the number of protons and neutrons which each have a spin of ½. Depending on their 
composition, atomic nuclei can have various spin configurations, but for nuclei with an 
even number of protons and neutrons, the formation of antiparallel spin pairs leads to a 
net spin of zero. Among these nuclei are carbon-12 (12C) and oxygen-16 (16O), which 
are highly abundant in biological tissue. Only their rare isotopes 13C and 17O have non-
zero spins. Hydrogen-1 (1H), with its core consisting of just a proton, has spin of ½ and 
makes up about 67% of the atoms in biological tissue, mainly in the form of water. In 
medical MRI we therefore rely on 1H nuclei (i.e., protons) and their different features 
such as their density or mobility to gain image contrast.  
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The spin property of a proton is directly linked to the existence of a magnetic moment 
. When an external magnetic field B0 is applied (by convention along the z-axis), this 
magnetic moment precesses around the axis of B0 at the frequency Ȧ0, which is called 
the Larmor frequency and is proportional to the external magnetic field (Fig. 3A).  
߱଴ ൌ ߛܤ଴                           (1.1) 
The constant Ȗ is the gyromagnetic ratio and characteristic for each nucleus. For 
protons, Ȗ is 42.6MHz/tesla.   
 
Figure 3: A) A proton possesses a magnetic moment ђ, which is the result of its intrinsic property 
of possessing a spin. An external, static magnetic field B0 will produce a torque that forces the 
magnetic moment to precess around the axis of the magnetic field with the frequency ʘ0. B) In 
an external magnetic field B0, proton spins can have two polarization states, one parallel and one 
antiparallel to B0. The energy difference between the two states is directly proportional to the 
Larmor frequency ʘ0 with the reduced Planck constant ̓ as the proportionality factor.  
In the quantum mechanical description, proton spins can be in two different states |Į> 
and |ȕ>, which are said to be polarized along the positive or negative z-axis, which 
commonly defines the direction of B0. These states are usually illustrated by arrows 
pointing along the positive or negative z-axis (Fig. 3B). The parallel state has lower 
energy than the antiparallel state and the energy difference equals ̓Ȧ0 and is 
proportional to B0 with equation (1.1). In thermal equilibrium, the high energy state is 
slightly less populated than the low energy state, which is determined by the Boltzmann 
distribution.  
ேഁ
ேഀ ൌ ݁
ି¾࣓૙ೖ೅         (1.2) 
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where N is the population of the |Į> and |ȕ> state, respectively, k is the Boltzmann 
constant and T the temperature.  
In an ensemble of many protons, the sum of magnetic moments of all protons will form 
a net magnetization M that is pointing along the z-axis, called longitudinal 
magnetization. This magnetization vector is manipulated and observed in MRI.  
By applying a radiofrequency (rf) -pulse with the amplitude B1, tuned to the resonance 
frequency Ȧ0 and perpendicular to B0, we can tilt the magnetization away from the z-
axis (Fig. 4).  
 
Figure 4: Trajectory of magnetization during the application of a 90° rf-pulse. 
This radiofrequency pulse is also called an ‘excitation pulse’. The angle by which the 
magnetization is rotated depends on the magnitude and duration of the pulse. A so 
called 90°-pulse, rotates M into the transverse plane, i.e. the x-y-plane, where it will 
precess around the z-axis and induce an electric current in a receiver coil, which is the 
measured signal in MRI.  
 
1.2.2 Relaxation 
T1 relaxation 
After excitation, the magnetization will turn back to its equilibrium state along the B0 
direction as the excited protons release energy to their surroundings. This regain of 
magnetization is called longitudinal or T1 relaxation, where T1 describes the time by 
which about 63% of the equilibrium magnetization M0 is reached after a 90°-pulse. The 
energy loss of protons can only occur if they encounter magnetic fields fluctuating at the 
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Larmor frequency, which is influenced by the mobility of protons and their 
surroundings. Thus, different types of tissue have different T1 relaxation times, creating 
contrast in T1-weighted MR images.  
 
T2 relaxation 
Another mechanism of loss of the detectable transverse magnetization is spin 
dephasing. After a 90°-pulse the spins are ‘in-phase’, but due to local, fluctuating 
magnetic field inhomogeneities, neighboring spins precess at slightly different 
resonance frequencies. This leads to a loss of phase coherence, and the magnetization in 
the transverse plane decays exponentially to zero.  The time by which about 63% of the 
original transverse magnetization has decayed is called transverse relaxation time T2. 
Slowly moving protons are more affected by field inhomogeneities and therefore have 
shorter T2 relaxation times than fast moving protons. Therefore, different tissues have 
different T2 relaxation times and thus different signal intensities in T2-weighted MR 
images.  
T2* relaxation 
Not only fluctuating magnetic fields created by molecular motion affect the dephasing 
of spins. Static magnetic field inhomogeneities, e.g. caused by air-tissue interfaces or 
biological tissue inhomogeneities, also accelerate spin dephasing. If both fluctuating 
and static magnetic field inhomogeneities are taken together, the time constant by which 
63% of the original transverse magnetization has decayed, is called T2*.  
ଵ
మ்כ
ൌ ଵ
మ்
൅ ଵ
మ்ᇲ
                    (1.3) 
Here, T2’ stands for the dephasing caused by fluctuating magnetic fields. 
 
Relaxation rate  
Apart from the relaxation time constants, also the relaxation rate is a frequently used 
term and is defined by 
ܴଵǡଶሺכሻ ൌ ଵ
భ்ǡమ
ሺכሻ          (1.4) 
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1.2.3 MRI contrast agents 
In MRI, contrast arises from the intrinsic T1 and T2 relaxation times, but contrast agents 
can be used to shorten these relaxation times and thereby change the image contrast. 
Commonly, contrast agents are injected intravenously (i.v.), distribute in the body and 
change the magnetic environment of neighboring protons. The relaxation rate is linearly 
dependent on the contrast agent concentration C [63-66] 
ܴଵǡଶ ൌ ܴଵ଴ǡଶ଴ ൅ ݎଵǡଶܥ               (1.5) 
 where R10,20 is the longitudinal or transverse relaxation rate without contrast agent and 
r1,2 is the relaxivity r1 or r2 of the contrast agent in units of (mmol/l)-1 s-1, which is 
characteristic for a contrast agent at a fixed magnetic field strength and temperature. 
There are different types of contrast agents of various sizes and relaxivities.  
Paramagnetic contrast agents 
Paramagnetic contrast agents are based on paramagnetic metal ions, of which 
gadolinium (Gd3+) is the most widely used one with 7 unpaired electrons and a high 
paramagnetic moment, which shortens the relaxation time of neighboring protons. [67]. 
Due to the high toxicity of free Gd3+, it is used in chelated form in contrast agent 
complexes. The ratio r2/r1 is relatively low for paramagnetic contrast agents, which 
makes them attractive for signal enhancement (or generation of ‘positive contrast’) in 
T1-weighted images [68].  
Superparamagnetic contrast agents 
Superparamagnetic contrast agents are ususally iron oxide particles containing 
thousands of iron ions, which form a strong magnetic moment when placed into an 
external magnetic field [67]. These particles have very high r2, which makes them 
excellent T2 and T2* contrast agents, also called ‘negative contrast agents’ [68]. 
 
1.2.4 Spatial encoding 
In MRI we measure the signal from the whole sample or body in the receiver coil and 
the signal needs to be spatially encoded to provide 2D or 3D images of the sample. By 
imposing spatially varying magnetic field gradients on the sample in three orthogonal 
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directions, we can change the resonance frequencies along these gradients. Commonly, 
a slice selecting gradient is turned on while the excitation pulse is applied to excite only 
a single slice of the subject with matching resonance frequencies. During signal 
acquisition, a frequency encoding gradient orthogonal to the selected slice is applied 
such that the frequency of each proton spin depends on its location along the gradient 
direction. Before signal acquisition, we apply a phase encoding gradient along the third 
dimension to impose a spatial variation in the phase of the proton spins. The signal is 
acquired many times while varying the phase encoding gradient amplitude, and the rate 
at which the phase varies depends on the location of the signal. This phase encoding 
step is mostly responsible for the relatively long MRI signal acquisition times, since the 
image resolution depends on the number of phase encoding steps. From the frequency 
information we obtain spatial information using Fourier transforms and receive an MR 
image.  
 
1.2.5 MRI pulse sequences 
In MRI, sequences of rf-pulses and magnetic field gradients are used to obtain an image 
and the sequences can be altered depending on the desired contrast. 
Spin echo sequence 
A frequently used pulse sequence is the spin echo sequence in which a 90°-pulse is used 
for excitation and a 180°-pulse for spin refocusing (Fig. 5). A 90°x-pulse flips the 
magnetization around the x’ axis so that it points along the y’. The signal decays 
exponentially due to dephasing of the spins within each voxel caused by magnetic field 
inhomogeneities. A 180°y-pulse rotates the dephasing magnetization vectors around the 
y’ axis. In the case of static magnetic field inhomoeneities, the protons retain their 
precession frequency and the magnetization vectors will rephase and create an echo, 
which is the recorded signal, at the time TE (echo time). Dephasing caused by 
fluctuating magnetic field inhomogeneities cannot be rephased and the signal decays 
with the time constant T2. This pulse sequence is repeated after the repetition time (TR) 
to enable phase encoding using varying gradients for each repetition. 
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Figure 5: Schematic description of the spin echo pulse sequence and the effect on the 
magnetization. Here the rotating frame is used for visualization, where the coordinate system is 
rotating around z at the Larmor frequency so that the precession of Mxy around z can be 
neglected. The x and y axes in this frame are marked as x’ and y’. 
Acquisitions using the spin echo sequence are time consuming, since TR has to be 
chosen according to the T1 of the sample so that the longitudinal magnetization has 
recovered sufficiently. The data acquisition can be accelerated by the application of 
several 180°-pulses within one TR. After each 180°-pulse, an echo is formed and can be 
acquired with a different phase encoding. This modification is called rapid acquisition 
with refocused echoes (RARE) in which the RARE factor specifies the number of 
echoes per TR.  
The spin echo signal intensity S can be expressed as   
̱ܵߩ௣ ൬ͳ െ ݁ି
೅ೃ
೅భ൰ ݁ି
೅ಶ
೅మ           (1.6) 
with ȡp being the proton density and T1 and T2 depending on the imaged sample or 
tissue. By changing TR and TE, the images can be weighted for T1 or T2. A short TR 
and TE results in T1-weighted images and a long TR and TE results in T2-weighted 
images.  
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Gradient echo sequence 
Another frequently used pulse sequence is the gradient echo. Here, shortly after the 90° 
excitation pulse, a gradient is switched on and accelerates dephasing of the 
magnetization. This is followed by a rephasing gradient of opposite direction, which 
rephases the spins to form an echo. This pulse sequence is faster than the spin echo 
sequence, but prone to signal loss caused by static field inhomogeneities of the main B0 
field, since there is no 180°-pulse. The signal therefore decays with the time constant 
T2*. This feature can be utilized for certain applications such as susceptibility contrast 
imaging (see Chapter 1.2.8).  
 
1.2.6 Diffusion weighted MRI 
Diffusion is the Brownian motion of molecules due to their thermal energy above 
absolute zero. With diffusion weighted (DW) MRI, this diffusion can be measured 
indirectly as a signal loss induced by diffusion sensitizing gradients applied during the 
MRI pulse sequence. The use of such gradients in a spin echo sequence is referred to as 
a Stejskal-Tanner sequence [69] for which a simplified pulse diagram is shown below 
(Fig. 6).  
 
Figure 6: Stejskal-Tanner pulse sequence with two diffusion sensitizing gradients  added to the 
spin echo sequence. The strength of the gradients is g, the gradient duration is ɷ and the time 
between the gradients is ȴ. 
The first gradient induces a phase shift in the spins, which is reversed with an identical 
gradient applied after the 180°-pulse. However, the spins can only rephase completely if 
they are stationary between the applications of the two gradients, because moving spins 
will experience a rephasing gradient that differs from the dephasing gradient. The faster 
the spins diffuse, the larger is the net displacement of the spins between the gradients 
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and the lower is the signal of the spin echo. The signal attenuation depends both on the 
diffusion and the pulse sequence characteristics and the relation can be expressed as  
ܵ ൌ ܵ଴݁ି௕ή஺஽஼         (1.7) 
where S is the measured signal intensity and S0 the intensity without diffusion 
sensitization. The apparent diffusion coefficient (ADC) is what we measure as 
diffusion, but may also include flow or gross motion, which is why we call it the 
‘apparent’ diffusion coefficient.  
The parameter b, referred to as ‘b-value’ indicates how strong the diffusion sensitization 
is and depends on the gyromagnetic ratio Ȗ, the gradient strength g, gradient duration į 
and time between the two gradients ǻ. 
ܾ ൌ ߛଶ݃ଶߜଶሺο െ ଵଷ ߜሻ         (1.8) 
To account for potential diffusion anisotropy, the gradients are often applied in three 
orthogonal directions and the signal of these three acquisitions is averaged. To compute 
the ADC, a set of MRI images is acquired for at least two different b-values and the 
ADC value is derived by exponential fitting.  
Contrast in DW-MRI arises from the different compositions of biological tissue, 
because water diffusion is restricted e.g. by cell membranes, macromolecules or other 
tissue components. Cancerous tissue usually has lower diffusivity compared to normal 
tissue, which is associated with a higher cell density of tumors, among other factors 
[70]. Expectedly, ADC has often been shown to be negatively correlated with cell 
density [71-73]. This property has made ADC a potential imaging biomarker for cancer 
detection and characterization and for assessment of treatment response. Treatment can 
change various features of tissue and cells. Cell death can be induced, which leads to a 
loss of cell membrane integrity and decreased cell density and may lead to increased 
diffusion as visualized in Fig.7.  
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Figure 7: Left: Free water diffusion is hindered by hydrophobic cell membranes of cells that are 
tightly packed. Right: Degenerative cell changes lead to lower cell density and cell membrane 
disintegration, allowing water to diffuse more freely.  
An increase in ADC is often reported after tumor treatment [74], but also decreases in 
ADC have been reported and may be attributed to cell swelling or the reduction of 
edema [75]. Although DW-MRI is already frequently added to conventional MR 
imaging protocols in oncology, a standardization of both DW-image acquisition (e.g. 
choice of b-values ) and analysis (e.g. mono-exponential vs multi-exponential fitting) is 
still needed [70]. In addition, the extent and timing of changes in ADC upon treatment 
need to be more reliably characterized before ADC can become a valid biomarker for 
treatment response [70].  
 
1.2.7 Dynamic contrast-enhanced MRI 
With dynamic contrast-enhanced (DCE) MRI the distribution of a positive contrast 
agent in the tissue can be followed over time by acquiring a series of images with 
identical geometry before and at several time points after contrast agent administration.  
The distribution of intravenously applied contrast agents in the tissue depends on 
perfusion and extravasation out of the blood vessels. DCE-MRI can therefore be used 
for cancer diagnosis due to vascular differences in normal and cancerous tissue. The 
shape of the signal enhancement curve depends on the tissue characteristics. For 
malignant tumors, the signal intensity vs. time curve is usually characterized by a fast 
signal enhancement, followed by a slow wash out of contrast agent from the tissue (Fig. 
8). The signal enhancement curve can be described by model-free parameters 
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characterizing the kinetics of the contrast agent in the tissue. These parameters include 
time to peak enhancement (TTP), fraction of enhancing voxels (FEV), the relative 
signal enhancement (RSI) and  area under the enhancement curve (AUC).The latter two 
are typically measured at set time points, e.g. 1 min post contrast administration.  
 
Figure 8: Signal enhancement curve showing the pre-contrast baseline signal and the fast signal 
enhancement upon contrast agent injection, which is followed by a slower washout. Semi-
quantitative parameters describing the enhancement curve are illustrated. TTP: time to peak, 
RSI1min: relative signal intensity 1min after contrast administration, AUC1min: area under signal 
enhancement curve 1 min after contrast administration - often referred to as initial area under 
the curve (IAUC). 
There are also numerous approaches for quantification of DCE-MRI data by 
compartment modelling. These approaches usually lead to an estimation of parameters, 
of which some are related to physiological characteristics. 
The extended Tofts-model is a frequently applied two-compartment model that assumes 
that the contrast agent is either intravascular or can diffuse into the extravascular 
extracellular space (EES) but remains extracellular [76] (Fig. 9).  
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Figure 9: Contrast agent flowing through a blood vessel and leaking out into the interstitium. 
Abbreviations: cp -  contrast agent concentration in the blood plasma, vp – blood plasma volume 
per unit volume of tissue, ce – contrast agent concentration in EES, ve -  volume of EES per unit 
volume of tissue, Ktrans and Ki - volume transfer constants between blood plasma and EES, kep - 
rate constant between EES and blood plasma. 
With the generalized form of the Tofts-model, three parameters can be estimated: Ktrans 
is the volume transfer constant between blood plasma and EES, ve is the volume of EES 
per unit volume of tissue, and vp is the blood plasma volume per unit volume of tissue 
[76,77]. Under mixed flow- and permeability-limited conditions, Ktrans depends on 
capillary permeability, vessel surface area and blood flow in the tissue [76]: 
ܭ௧௥௔௡௦ ൌ ܧ݂ ή ܨ ή ߩ௧ ή ሺͳ െ ܪܿݐሻ              (1.9) 
where Ef is the extraction fraction, F the blood flow per unit mass of tissue, ȡt the tissue 
density and Hct the blood hematocrit [76]. Alternative notations include 
ܭ௧௥௔௡௦ ൌ  ሺͳ െ ܪܿݐሻܭ௜ ൌ ݇௘௣ ή ݒ௘      (1.10) 
where Ki represents the transfer constant from plasma to EES and kep the rate constant 
between EES and blood plasma [76,78]. 
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In the Tofts-model, the estimated parameters Ktrans, ve and vp are derived from the time 
dependent contrast agent concentration in the tissue Ct(t) and in the blood plasma Cp(t) 
according to [76,77]  
ܥ௧ሺݐሻ ൌ ܭ௧௥௔௡௦ ׬ ܥ௣ሺ߬ሻ௧଴ ή ݁ିሺ௄
೟ೝೌ೙ೞȀ௩೐ሻሺ௧ିఛሻ݀߬ ൅ ݒ௣ܥ௣(t)              (1.11) 
Ct(t) can be derived from the signal enhancement curve measured with DCE-MRI. To 
convert the signal S(t) to Ct(t), knowledge of the dependence of the signal on the MR 
pulse sequence is necessary. In the case of a T1-weighted spin echo sequence, the signal 
depends mostly on T1 (see equation 1.6), which in turn is linearly dependent on the 
contrast agent concentration in the tissue according to (1.5). The baseline T1 relaxivity 
of the tissue, T10, can be determined by pre-contrast T10-mapping using a separate pulse 
sequence. The ratio of the signal S to the baseline signal S0 from (1.6) together with 
(1.5) can then be used to determine Ct (t). The contrast agent concentration in the 
plasma Cp(t) is usually referred to as the vascular or arterial input function (VIF or AIF) 
and needs to be measured separately e.g. by MRI [79,80] or blood sampling [81]. In 
many cases it is challenging or too time consuming to acquire a VIF for each patient, so 
often population based VIFs are utilized, although this may leads to a bias in the 
computation of Ktrans, ve and vp [80].  
DCE-MRI is increasingly used in drug trials for monitoring of tumor vasculature. For 
the assessment of response to drugs directly or indirectly targeting the vasculature it is 
necessary to derive quantitative parameters [82]. Ktrans and AUC are frequently reported 
values in studies quantifying changes in tumor vasculature [83]. However, the 
dependence of these parameters on both blood flow and vessel permeability makes 
interpretation of how such parameters correlate with tumor physiology and vascular 
function difficult. Moreover, a standardization of both data acquisition and analysis is 
desirable so that data is comparable between studies.  
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1.2.8 Steady state susceptibility contrast MRI 
Steady state susceptibility contrast (SSC) MRI can be used for the indirect assessment 
of vascular characteristics within a voxel. Here, usually superparamagnetic contrast 
agents are used due to their  high r2 values [67].  
Intravascular superparamagnetic iron oxides lead to an increased difference in magnetic 
susceptibility between blood vessels and the surrounding tissue. This leads to magnetic 
field gradients, which cause an increase of both R2 and R2* relaxation rates and 
consequently a signal loss after administration of the contrast agent. The relaxation rates 
increase with contrast agent concentration, but are also dependent on the vascularization 
of the tissue [84]. For instance, R2* increases with increasing fractional blood volume 
(FBV) of the tissue, while R2 increases only slightly [84]. Tropres et al. have derived an 
expression for the estimation of the fraction of blood volume in the tissue (FBV) 
depending on the difference of R2* in an MRI voxel before and after contrast agent 
administration [85] 
ܨܤܸ ൌ ଷସగ
οோమכ
ఊοఞ஻బ              (1.12) 
in which Ȗ is the gyromagnetic ration of the 1H nucleus, ǻʖ the susceptibility difference 
between blood with and without contrast agent and B0 the strength of the external 
magnetic field. Similarly, ǻR2 and ǻR2* can be used to estimate vessel size [85,86] or 
blood vessel density [87]. 
Currently, SSC-MRI is not widely used in humans, because clinically approved contrast 
agents have short blood plasma half-lives. However, this method may become of 
interest when suitable contrast agents become available. A compound that would make 
a suitable contrast agent is ferumoxytol, a superparamagnetic iron oxide with long 
circulation half-life, which is used to treat iron deficiency anemia in patients with 
chronic kidney disease. Recently, ferumoxytol has been used off-label in clinical SSC-
MRI studies [88,89]. 
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1.3 X-ray computed tomography 
X-ray computed tomography (CT) was introduced in the early 1970s by Allan MacLeod 
Cormack and Godfrey Newbold Hounsfield [90,91]. For their work, they received the 
Nobel Prize in Physiology or Medicine “for the development of computer assisted 
tomography” in 1979. 
The image contrast in CT arises from the varying X-ray attenuation properties of 
different types of tissue. The attenuation of a monoenergetic X-ray beam by a 
homogenous substance is described by the Lambert-Beer law: 
ܫሺݔሻ ൌ ܫ଴݁ିఓ௫                  (1.13) 
with I0 being the intensity emitted by the X-ray source and I(x) the X-ray intensity after 
traversing a distance x through a material with an attenuation coefficient . Importantly, 
 is dependent on the X-ray energy and the density and atomic number of the material. 
For example, bones attenuate X-rays more than soft tissue. For inhomogeneous 
material, such as biological tissue, the signal intensity can be written as an integral in 
which the attenuation coefficient varies for different locations x along the path: 
ܫሺݔሻ ൌ ܫ଴݁ି׬ఓሺ௫ሻௗ௫                            (1.14) 
If the object is scanned at a fixed angle, a 2D X-ray image is created in which the image 
intensity represents the average absorption in the beam direction. To gain depth 
information, the object needs to be scanned at different angles over 180 degrees from 
which a 3D volume is created after tomographic image reconstruction, which is 
described in detail in [92].  
For CT of small animals or specimen, bench-top micro-CT (CT) scanners are 
available that achieve images with isotropic voxel sizes down to ~1m [93,94]. 
Scanners using synchrotron radiation can acquire images at even lower resolution but 
are of higher financial cost and limited availability, so they cannot be used routinely for 
large scale experiments [94]. The availability of (CT) scanners and their use in 
preclinical research have greatly increased for the past decade [95-97]. 
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CT for vascular imaging 
Preclinical applications of CT include bone, lung, cardiac and vascular imaging 
[95,97]. High resolution structural imaging of blood vessels in 3D on the whole tumor 
level and without tissue destruction can be best performed by CT [93]. In vivo imaging 
is often advantageous over ex vivo imaging, especially because it allows for longitudinal 
studies and recapitulates the true in vivo environment. However, the in vivo CT 
resolution is not sufficient to image the smallest capillaries, which can be as small as 
4m in diameter in mice [98], so ex vivo imaging is performed when very high 
resolution is desired. 
Since CT provides very low endogenous contrast between blood vessels and 
surrounding tissue, contrast agents of high radio-density have been developed. For ex 
vivo imaging, animals are commonly perfused with the contrast agent via the still 
beating heart. After perfusion, the contrast agent is required to solidify. Other contrast 
agent properties required for an exact analysis of the vascular network include a low 
viscosity for complete filling of small vessels, absence of extravasation, and limited 
shrinkage upon hardening [93]. 
One frequently used contrast agent is Microfil (MV-series) (Flow Tech, Inc., Carver, 
MA, USA), a lead-containing silicone rubber that polymerizes approximately 90 
minutes after mixing with a curing agent with very little shrinkage. This method allows 
the intact tumor to be scanned by CT after which other analyses such as 
histopathology can be performed. One disadvantage is, however, that background signal 
from the tumor tissue can make segmentation of small vessels challenging. Microfil has 
been used to compare the vascularization of different tumor models [99] or assess 
treatment-induced vascular changes [100-103]. 
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1.4 Histopathology  
Histopathology refers to the study of the cytology and structure of diseased tissue at the 
microscopic level. Today, the histopathological examination of tissue biopsies is a 
standard for the diagnosis of cancer.  
Tissue samples are commonly sectioned into thin slices (commonly 4m thick) and 
stained to visualize cellular components or provide contrast between different 
structures. A frequently used staining technique is called H&E, utilizing a combination 
of hematoxylin, which stains cell nuclei blue, and eosin, which stains cytoplasm pink. In 
addition, saffron can be used to stain collagen fibers yellow. This triple stain is called 
HES. Both techniques produce stains suitable for a cellular characterization of cancer 
tissue using light microscopy.  
 It is also possible to stain antigens in the tissue with antibodies conjugated to 
fluorescent probes or enzymes with chromogenic or fluorescent substrates.  This 
technique is called immunohistochemistry.  
 
1.5 Intravital microscopy 
While histopathology allows imaging of tumor features at subcellular resolution, this 
method needs to be performed ex vivo, which precludes the longitudinal study of 
physiological processes. The previously discussed in vivo imaging modalities such as 
MRI and CT can be performed at various time points. However, they lack the resolution 
for imaging at the cellular level. Intravital microscopy (IVM) is a unique method for 
repeated microscopic in vivo imaging of intact tissue and has been an invaluable tool for 
the study of gene expression, angiogenesis, blood flow, vascular permeability, pH, 
transport of molecules and cells, cell-cell interactions and other biological processes in 
tumor models [16,104-106]. IVM requires tissue preparation, an optically detectable 
probe and a microscope [107].  
Window chamber models are a way of preparing tissue so that the area of interest can be 
observed through a glass window, which is surgically implanted into the dorsal skin flap 
or cranium [16]. Dorsal window chambers are frequently used to look at normal tissue 
or tumors. A dorsal skin flap is prepared by dissecting away one side of the skin flap so 
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that the vasculature and connective tissue of the other side become visible and is 
covered by a glass. A frame holds the skin flap and glass cover in place [105]. This 
setup enables the study of normal blood vessels. Alternatively, tumor cells can be grown 
underneath the glass for the study of tumor tissue or vasculature. While dorsal window 
chambers are a superb technique for high resolution imaging of many physiological 
features of tumors, there are some important limitations. First, tumors grown in window 
chambers may differ from orthotopically grown tumors due to a different tumor 
environment [108]; and second, only a thin tumor of up to about 500 m can be grown 
below the glass cover, so that necrotic or hypoxic regions, which are frequently 
observed in orthotopic or subcutaneous tumours, rarely form [106]. 
Frequently used optical probes are, for instance, fluorescent drugs to study 
pharmacokinetics, probes responding to changes in pH to study the tumor 
microenvironement or probes targeting certain receptors to quantify receptor expression 
and binding [107]. 
Advanced fluorescent microscopy techniques such as confocal laser scanning 
microscopy or multiphoton microscopy enable 3D imaging due to their ability to focus 
on selected planes at different tissue depths [106]. However, the penetration depth of 
light in tissue is limited to about 1mm [109]. 
 
1.6 Multifunctional nanoparticles 
In recent years, advances in nanotechnology have made it possible to design 
multifunctional nanoparticles that can be used for a large variety of applications such as 
molecular imaging and drug delivery.  
One group of such particles are lipid based, consisting mainly of amphiphilic lipids 
which consist of a polar head group (hydrophilic) and a non-polar tail (hydrophobic). In 
an aqueous environment, amphiphiles spontaneously assemble into aggregates such as 
micelles or liposomes. A mixture of lipids, water and oil is the basis for the formation of 
emulsions, one type being oil-in-water nanoemulsions, which consist of an oil core 
separated from water by a lipid monolayer [110].  
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The shape and size of these aggregates depends on the size and charge of the 
hydrophilic and hydrophobic parts and the environment (e.g. pH, temperature, 
concentration). The aggregation is driven by water’s repulsive interactions with the 
hydrophobic parts and associative interactions with the hydrophilic parts. Phospholipids 
are often used for the synthesis of nanoparticles [111] and are also the main constituents 
of biological cell membranes.  
Nanoparticles can serve multiple functions. One is the delivery of drugs to solid tumors 
through ‘passive targeting’. Nanoparticles can leak out and accumulate in tumors due to 
the high permeability of tumor vessels to macromolecules, which cannot pass the walls 
of blood vessels in normal tissue, and the limited lymphatic drainage in tumors. This is 
called the “enhanced permeability and retention (EPR) effect” [112]. This effect is 
exploited, for example, to treat ovarian cancer with liposomal doxorubicin [10]. Another 
application of high interest is molecular imaging. Nanoparticles can contain contrast 
agents for MRI such as gadolinium or iron, which affect the relaxation times. They can 
also be fluorescently labeled, which allows for their detection using various 
fluorescence microscopy techniques [111]. In addition, targeting ligands can be 
conjugated to nanoparticles, which enables ‘active targeting’ of nanoparticles to specific 
cell receptors [111].Several of these functionalities can be combined when designing 
nanoparticles, which makes them very versatile and allows them to be tailored for a 
variety of preclinical applications. 
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2 Aims 
The main objectives of this thesis were to develop and assess the performance of multi-
modal imaging methodologies for characterizing physiological tumor features and their 
changes induced by treatment. More specifically, the goals were to: 
x develop co-registration procedures for multi-modal imaging of tumor vasculature. 
 
x assess the performance of in vivo MR imaging biomarkers for tumor cellularity, 
vascular morphology and vascular function by comparison with suitable ex vivo 
imaging methods. 
 
x characterize the cellular and vascular response of two different ovarian cancer 
xenograft types to PI3K/mTor inhibition. 
 
x develop multi-modal imaging procedures for assessing nanoparticle targeting 
kinetics in vivo on the whole tumor level. 
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3 Materials and methods 
This thesis comprises three papers in which various imaging methods were used to 
quantify characteristics or treatment response of human cancer xenografts. The material 
and methods used in these studies are summarized in Table 1. 
Table 1 Summary of materials, methods and data analysis techniques used in papers I-III 
  Paper I Paper II Paper III 
Materials 
Cell lines MDA-MB-231 TOV-112D TOV-21G 
TOV-112D 
HUVEC 
 
Drugs - BEZ235 - 
 
MRI contrast agent Feridex Omniscan 
Nanoemulsion 
containing Gd-
DTPA 
Methods 
in vivo MRI SSC-MRI DW-MRI 
DCE- MRI 
DW-MRI DCE-MRI 
 
ex vivo MRI micro- MRI anatomical MRI - 
 
ex vivo CT CT angiography CT angiography - 
 
IVM - - vascular input function 
 
Histopathology - HES Ki-67 
CD31 
DAPI 
 
Protein expression - Western blotting - 
Data 
analyses DCE-MRI Tofts - Tofts 
 
SSC-MRI FBV - - 
 
DW-MRI monoexponential fitting 
monoexponential 
fitting - 
 
CT angiography FBV FBV, vessel density, radius, length - 
Abbreviations: HUVEC: human umbilical vein endothelial cells, Gd-DTPA: Gadopentetic acid, MRI: 
magnetic resonance imaging, SSC: steady state susceptibility contrast, DCE: dynamic contrast enhanced. 
DW: diffusion weighted, CT: computed tomography, IVM: intravital microscopy, HES: Hematoxylin-Eosin-
Saffron, FBV: fractional blood volume 
 
3.1 Cell lines and animal models 
In all three papers, cell line-derived xenografts were grown in immunodeficient nude 
mice. In paper I the animal experiments were conducted in accordance with the Animal 
Care and Use Committee guidelines at the Johns Hopkins University, Baltimore, MD, 
USA. For paper II and III all animal procedures were approved by the Norwegian 
Animal Research Authority, and carried out according to the European Convention for 
the Protection of Vertebrates used for Scientific Purposes.   
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3.1.1 MDA-MB-231 human breast cancer cell line 
The MDA-MB-213 breast cancer cell line was isolated from a pleural effusion of a 51 
year-old breast cancer patient in 1973 [113]. Today, this aggressive cell line is well 
characterized and one of the most widely used breast cancer cell lines in research 
experiments [114,115]. The cells express high levels of VEGF in vitro and xenografts 
established from these cells are reported to be well vascularized [115]. 
For paper I, MDA-MB-231 cells were grown in RPMI-1640 medium supplemented 
with 10% fetal bovine serum and penicillin-streptomycin. Xenografts were grown 
orthotopically in female athymic NCr nu/nu mice after injection of three million cells in 
to the left thoracic mammary fat pad.  
 
3.1.2 TOV-21G and TOV112D human ovarian cancer cell lines 
The two ovarian cancer cell lines used in this work were established directly from 
malignant ovarian tumors of different clinical phenotypes. The TOV-21G cell line 
originates from a clear cell carcinoma while the TOV-112D cell line was derived from 
an endometrioid carcinoma [116].  
In paper II, TOV-21G and TOV-112D cells were characterized for their PI3K signaling 
activity and xenografts were grown for in vivo imaging by injection of five million cells 
subcutaneously into the hind limb of female athymic BalbC nu/nu mice. For paper III 
only TOV-112D xenografts were used. The cells were grown in a 1:1 mixture of 
Medium 199 (Gibco 41150) and MCDB 105 Medium (Sigma M6395) supplemented 
with 15% fetal bovine serum and 0.05mg/ml gentamicin.  
 
3.2 Drug BEZ235 
NVP-BEZ235 (or BEZ235) is a dual pan-class I PI3K and mTOR kinase inhibitor 
developed by the Global Discovery Chemistry Group (Novartis Pharma, Novartis 
Institutes for Biomedical Research Oncology) [33]. Inhibition of both mTORC1 and 
mTORC2 has been reported [33]. The drug has reached phase 2 clinical trials 
(clinicaltrials.gov).  
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For paper II, BEZ235 was purchased from LC Laboratories, Woburn, MA, USA and 
dissolved to 14 mg/ml in dimethyl sulfoxide (DMSO, Sigma-Aldrich #D-5879) under 
gentle heating. It was then diluted to a final concentration of 6.5mg/ml using 
polyethylene glycol (PEG300, Sigma-Aldrich #20237-1) and administered to the mice 
at a dose of 65 mg/kg/day by oral gavage on three consecutive days.  
 
3.3 In vivo MRI 
In all three papers, in vivo MRI was used to image tumor xenografts grown in mice. An 
overview of the MR sequences for each paper is given in Table 2.  
 
3.4 CT 
For paper I, CT of breast xenografts was performed to validate in vivo MRI data and 
measure the FBV. For paper II, CT of ovarian xenografts was conducted to measure 
FBV, vessel radius, length and density. In both papers, mice were perfused 
intracardially with saline, followed by formalin and Microfil. The compound 
polymerizes after the perfusion to form a radio-opaque vascular cast.   
Micro-CT was performed by Numira Biosciences (Salt Lake City, UT, USA) on a high-
resolution, volumetric CT scanner (CT40, ScanCo Medical, Brüttisellen, CH). All 
images were acquired at 8 m isotropic resolution with 55 kVp, 300 ms exposure time, 
2000 views and 5 frames per view. 
 
3.5 Oil-in-water nanoemulsions 
In paper III, multi-functional and multi-modal oil-in-water nanoemulsions were used for 
targeting and imaging of Įvȕ3 integrin in angiogenic tumor blood vessels. The 
nanoparticles were synthesized by Sjoerd Hak and characterized and described in a 
previous paper [117]. The nanoemulsion consists of a soybean oil core and a 
phospholipid mixture forming a monolayer, stabilized by cholesterol. For MR-contrast, 
the headgroups of one phospholipid type contained gadolinium. For intravital imaging 
and histology, the nanoemulsions contained two types of fluorescent molecules in the 
oil core and the headgroups of the phospholipids, respectively. The nanoparticles were 
conjugated to RGD, which served as a targeting ligand to Įvȕ3 integrin.  
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Table 2 Detailed MRI sequence parameters used in papers I-III 
 Paper I Paper II Paper III 
Hardware    
MR scanner Bruker Biospin  Bruker Biospec  Bruker Biospec  
field strength 9.4T 7.05T 7.05T 
transmit coil 18mm solenoid  72mm volume 72mm volume receive coil quadrature surface quadrature surface 
Geometry    
FOV (mm2) 14 × 14 23 × 23 25.2 ×14.4 
slice thickness (mm) 1 0.692 1 
interslice distance (mm) 1 1 n.a. 
number of slices 3-8  5 1 
high resolution images    
sequence  RARE spin-echo FLASH 
TR (ms)  2000 350 
TE (ms)  12 5.4 
RARE factor  8 n.a. 
Matrix  256 × 256 224 × 128 
in plane resolution (m)  90 112.5 
number of averages  1 8 
DW-MRI    
sequence RARE EPI  
Preparation mode spin-echo spin-echo  
TR (ms) 1000 3000  
TE (ms) 26.6 28  
b-values (s/mm2) 0, ~300 0, 100, 300, 600, 1000  
Matrix 128 × 128 64 × 64  
in plane resolution (m) 100 359  
number of averages 2 1  
number of segments n.a. 4  
gradient orientations 3 orthogonal 3 orthogonal  
DCE-MRI    
Matrix  64 × 64 56 × 32 
in plane resolution (m)  359 450 
T1-map    
sequence  RARE RARE 
TR (ms)  150, 750, 1500, 2500, 
4500, 1200 
150, 750, 1500, 2500, 
4500, 12500 
TE (ms)  7.2 7 
RARE-factor  2 2 
zerofill accelleration  1 1.34 
number of averages  1 1 
Dynamic series    
sequence  RARE RARE 
TR (ms)  300 300 
TE (ms)  7.2 7 
RARE-factor  4 2 
temporal resolution (s)  4.8 21.6 
number of repetitions  200 60 
number of averages  1 6 
zero fill accelleration  1 1.34 
Injection    
Gd Dose (mmol/kg)  0.3 (Omniscan) 0.02 (in nanoemulsions) 
baseline scans  10 5 
injection duration (s)  ~ 4 ~ 20 
SSC-MRI    
sequence MGE   
TR (ms) 800   
TE (ms) 4.2, 7.2, 10.2, 13.2, 
16.2, 19.2 
  
flip angle (º) 90   
number of averages 4   
Matrix 128 × 128   
in plane resolution (m) 100   
iron dose mg/kg 25 (Feridex)   
Abbreviations: FOV: field of view, TR: repetition time, TE: echo time, RARE: rapid acquisition with 
relaxation enhancement, FLASH: fast low angle shot, MGE: multi-echo gradient-echo, EPI: echo planar 
imaging 
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3.6 Intravital microscopy 
For paper III, IVM was used to acquire a vascular input function for DCE-MRI analysis 
using the fluorescent nanoemulsion labeled with GD-DTPA. The window chamber 
preparation was performed at the Department of Physics (NTNU) and confocal 
microscopy for the acquisition of the VIF was performed by Sjoerd Hak.  
 
3.7 Histopathology 
For paper II, histopathology of treated and untreated xenografts was performed to assess 
changes in cell morphology and proliferation after PI3K/mTOR inhibition. Cell 
morphology was qualitatively assessed in HES stained sections. Sections were also 
stained for Ki-67, which is a protein present only in proliferating cells [118] and the 
density of stained cell nuclei was visually assessed. 
In paper III, histology was performed to assess the distribution of nanoemulsion in 
tumor tissue in relation to blood vessels. The protein CD-31 (also called PECAM-1) is a 
cell adhesion molecule highly expressed by endothelial cells [119] and was 
fluorescently stained to visualize blood vessels. Cell nuclei were counterstained with 
4',6-diamidino-2-phenylindole (DAPI), which is a probe binding specifically to a certain 
DNA sequence, upon which it forms a fluorescent complex [120]. The fluorescence was 
detected using an inverted fluorescence microscope Olympus IX71 and images were 
acquired using a 20X objective. 
  
3.8 Protein Expression 
For paper II, protein expression of TOV-112D and TOV-21G tumor cells was analyzed 
using western blotting by Prof. Bjørkøy’s group at Høgskolen i Sør-Trøndelag (HiST). 
Proteins were separated by electrophoresis and the expression of total Akt, p-Akt, p-S6 
and total S6 was detected with specific antibodies and visualized using fluorescent 
secondary antibodies. The expression of p-Akt was also visualized in histology sections 
of TOV-112D and TOV-21G xenografts by labelling with fluorescent antibodies. The 
fluorescent intensity of both cell extracts and xenograft sections was assessed using the 
Odyssey Infrared Imaging System and Image Studio 3.1 software (LI-COR Biosciences,  
Lincoln, NE, USA). 
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4 Summary of papers 
Paper I 
Multiscale and multi-modality visualization of angiogenesis in a human breast 
cancer model 
Jana Cebulla, Eugene Kim, Kevin Rhie, Jiangyang Zhang and Arvind P. Pathak 
Angiogenesis. 2014 Jul;17(3):695-709. 
Angiogenesis is of high importance for cancer growth, invasion and metastasis. A better 
understanding of tumor blood vessel characteristics is therefore necessary, for instance 
to facilitate the development of new cancer treatment strategies.  
In this paper, we developed multiscale and multi-modality imaging techniques for 
studying tumor blood vasculature in human breast cancer xenografts grown from MDA-
MB-231 cells. On the macroscopic scale, we used in vivo SSC-MRI to create FBV maps 
with 100 m in plane resolution and in vivo DW-MRI to acquire complementary 
information on tumor cellularity. On the microscopic scale, ex vivo CT was performed 
to image the vasculature at the microvessel level with 8 m isotropic resolution. Due to 
the large disparity in spatial resolution, we used ex vivo MRI to aid the co-registration 
between in vivo MRI and CT. Suitable vessel extraction and intermodality co-
registration techniques were developed.  
The tumor FBV was computed for each imaging modality. It was found that the FBV 
derived from both MRI methods was overestimated compared to the CT although the 
MRI and CT FBV showed the same spatial distribution. Importantly, all three 
modalities were able to depict the decreased FBV in the tumor center compared to the 
rim. Finally, we demonstrated an application of our multi-modality imaging approach in 
which we overlaid the high-resolution CT tumor blood vessels onto diffusion maps 
from the in vivo MRI data. This way we were able to visualize the poor blood supply in 
necrotic tumor regions.  
The methods developed in this paper can facilitate the integration between multiscale 
and/or multi-modality data related to angiogenesis in pre-clinical cancer models. 
Several methods developed here were used in paper II.  
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Paper II 
MRI Reveals the in Vivo Cellular and Vascular Response to BEZ235 in Ovarian 
Cancer Xenografts with Different PI3-Kinase Pathway Activity 
Jana Cebulla, Else Marie Huuse, Kristine Pettersen, Anna van der Veen, Eugene Kim, 
Sonja Andersen, Wenche S. Prestvik, Anna M. Bofin, Arvind P. Pathak, Geir Bjørkøy, 
Tone F. Bathen, Siver A. Moestue 
Br J Cancer 2015 Feb 3;112(3):504-13. 
The purpose of this study was to investigate MRI biomarkers for response to 
PI3K/mTor inhibition. The cellular and vascular responses of ovarian xenografts to 
treatment with BEZ235 were measured using MRI, CT and immunohistochemistry. 
First, the PI3K activity of the cell lines was measured using immunoblotting, which 
revealed low PI3K signaling activity in TOV-112D cells and high activity in TOV-21G 
cells, suggesting that the latter is more responsive to treatment.  
After the establishment of subcutaneous xenografts in mice, the tumors were imaged 
before and three days after treatment with 65 mg/kg BEZ235 using DW-MRI and DCE-
MRI. A strong treatment response was found for the TOV-21G xenografts in form of a 
decrease in tumor volume and decreased cell proliferation, while only a slight growth 
inhibition was found for the TOV-112D xenografts. DW-MRI measured a strong 
treatment response in TOV-21G xenografts as ADC values increased significantly. 
DCE-MRI displayed elevated ve for both xenograft types and suggested an improved 
vascular function to a similar extend in both treated xenograft models. Changes in 
vascular morphology could not be ascertained in this study.  
The results of this study suggest that DW-MRI may be a valuable tool for assessing 
response to PI3K/mTor inhibition in vivo. DCE-MRI can give additional information on 
vascular function and compartment modeling can yield quantitative parameters. 
However, the physiological meaning of those parameters is often difficult to interpret.  
In contrast, the diffusion coefficient derived from DW-MRI can be more easily 
interpreted, which is why we suggest that ADC be further evaluated as a biomarker for 
response to targeted drugs.  
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Paper III 
Periodicity in tumor vasculature targeting kinetics of ligand-functionalized 
nanoparticles studied by dynamic contrast enhanced magnetic resonance imaging 
and intravital microscopy 
Sjoerd Hak, Jana Cebulla, Else Marie Huuse, Catharina de L. Davies, Willem J.M. 
Mulder, Henrik B.W. Larsson, Olav Haraldseth 
Angiogenesis. 2014 Jan;17(1):93-107. 
In this paper we studied the accumulation of nanoparticles in TOV-112D ovarian 
xenografts using DCE-MRI. The multi-modality nanoemulsions contained gadolinium-
lipids for MR contrast enhancement and a fluorescent dye for IVM. In addition, the 
emulsions were RGD-conjugated, which enabled them to bind to Įvȕ3-integrin, which 
are receptors highly expressed on angiogenic endothelial cells.  
The in vivo nanoemulsion kinetics were studied with DCE-MRI on the whole tumor 
level. Compartment modeling was performed to quantify the targeting rates of 
nanoemulsions targeted to Įvȕ3-integrin using the MR contrast enhancement curve and a 
VIF. For this purpose, dorsal window chambers were implanted on healthy mice and 
confocal laser scanning microscopy was used to obtain the VIF after injection of 
fluorescent nanoemulsions. The results were validated by investigating the Įvȕ3-integrin 
targeting dynamics with HUVEC cells in vitro.  
DCE-MRI showed that the RGD-conjugated nanoemulsions accumulated faster in the 
tumor rim compared to non-targeted nanoemulsions. Moreover, a fluctuation was found 
in the contrast enhancement curve for the targeted but not for the non-targeted 
nanoemulsion. The in vitro experiments strongly indicated that this fluctuation was 
caused by integrin dynamics, i.e. integrin binding, internalization into cells and 
recycling to the cell surface. 
This study demonstrated that DCE-MRI may be a suitable tool for the investigation of 
targeted nanoparticle kinetics in cancer. In addition, this method may be a unique tool 
for the quantification of endothelial cell receptor expression levels and study of integrin 
dynamics in vivo, which are still insufficiently characterized. 
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5 Discussion 
Multi-modal imaging is becoming the standard in clinical cancer care because a 
combination of complementary data allows for more precise cancer diagnosis and 
staging, treatment planning and assessment of treatment response. Also for preclinical 
research, multi-modal imaging is often used in order to characterize physiological 
properties of tumors in detail. In addition, the development of new, clinically 
translatable imaging biomarkers often relies on multi-modal imaging for biomarker 
validation.  
In all papers that compose this thesis, several imaging modalities were combined to 
either take advantage of the complementary information or to validate imaging 
biomarkers. The multi-modal approaches were then used to explore vascular features of 
cancer or to assess response to treatment.  
 
5.1 Multi-modal imaging for validating imaging biomarkers 
Non-invasive imaging modalities are valuable tools for cancer diagnosis and assessment 
of treatment response. Especially for novel targeted drugs, for which it is difficult to 
predict response in individual patients prior to treatment, novel biomarkers for response 
are needed. Clinical imaging modalities such as MRI, CT and ultrasound have a 
relatively low resolution that is sufficient for anatomical imaging and measuring tumor 
size but not for directly visualizing e.g. small capillaries. However, with the use of 
mathematical modelling and under certain assumptions, we can use these imaging 
modalities to indirectly characterize physiological measures such as tumor 
vascularization (e.g. FBV, vessel size and density), vascular function (e.g. permeability, 
blood flow) and tumor cellularity. 
In this thesis, in vivo MRI was used to measure several imaging biomarkers related to 
vascular or cellular characteristics. All of these biomarkers were derived indirectly from 
the MR images using data fitting or mathematical modelling. The assumptions that 
underlie these derivations do not always apply for complex in vivo systems. Thus, 
before these biomarkers can be used clinically, they first need to be validated by other 
methods that are well-established in the clinic or that can reliably measure the 
Discussion 
___________________________________________________________________ 
44 
 
underlying physiological properties directly. Unfortunately, such validation is usually 
challenging. Multi-modal imaging exploits the advantages of each imaging modality, 
but the modalities may show great differences e.g. in resolution or contrast mechanism 
and can sometimes not be directly correlated. Still, further improvements in co-
registration techniques like in paper I and systematic comparison of in vivo with ex vivo 
imaging as performed in papers I-III will help to improve the availability of validation 
tools.  
 
5.1.1 Validating SSC-MRI-derived tumor FBV using CT 
In paper I, SSC-MRI was used to estimate the FBV in breast tumor xenografts and 
compared to the FBV derived from co-registered CT images. High resolution CT has 
the advantage of visualizing the 3D vasculature in great detail and is therefore 
frequently regarded as the ‘gold standard’ for analyzing structural features of tumor 
vasculature. Our results showed that the distributions of FBV values in the tumors were 
similar for the SSC-MRI and CT data. In a follow up study, it was shown that median 
tumor FBV measured by SSC-MRI was significantly correlated with that measured by 
CT [121]. Ungersma et al. performed the same comparison of SSC-MRI and CT-
derived mean FBV but found no correlation, which may be caused by the exclusion of 
non-viable tissue from the MRI but not the CT data. In both their and our studies, 
SSC-MRI overestimated the absolute FBV values in comparison to CT, and Kim et al. 
suggested that relative SSC-MRI biomarkers (proportional to a physiologic measure) 
may be of greater value than SSC-biomarkers with absolute units [121]. This may be 
important for the clinical use of SSC-MRI biomarkers, as the use of relative biomarkers 
may still be helpful e.g. for assessing relative changes in the blood vasculature induced 
by treatment. It should not be forgotten though, that CT also has methodological 
challenges as complete filling of the tumor vasculature is not always achieved [122] or, 
as in our case, the resolution of 8 m may not be sufficient to visualize the smallest 
capillaries. This can diminish its value as the ‘gold standard’. Still, CT has clear 
advantages over histological hot spot analysis and is a powerful technology for 
assessing vascular morphology.  
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5.1.2 Validating changes in ADC as a biomarker for cellular response using 
histology 
DW-MRI is sensitive to water motion. It is a relatively fast imaging technique that does 
not require the application of contrast agent or complex computations to quantify ADC 
values, to name a few advantages of this imaging modality. DW-MRI is used for cancer 
detection, but it is also a promising biomarker for treatment response to cytotoxic and 
antivascular drugs [70]. However, there are no accepted standards for distinguishing 
between malignant and benign tissue, nor are there validated and quantified 
relationships between changes in ADC and response to treatment.  It is also not clear 
whether DW-MRI is useful for monitoring response to other targeted therapies, and 
generally, DW-MRI is not completely understood at the cellular level [70].  In paper II, 
we therefore validated treatment-induced changes in ADC with histology. Treatment-
induced elevation of ADC is often attributed to increased apoptosis [70], but 
quantification of apoptosis in tissue sections is challenging, because it can be induced 
through different biochemical mechanisms and can occur at different time points 
depending on the type of cancer and drugs involved [123]. This makes it difficult to 
identify a universal biomarker for apoptosis. In paper II, we therefore chose to assess 
drug induced changes in cellular characteristics by staining for the Ki-67 protein, which 
is a widely used proliferation marker [118]. Although Ki-67 expression does not 
necessarily correlate directly with ADC [124,125], it confirmed that the increase in 
ADC may be caused by changes on the cellular level as cell proliferation decreased 
markedly. In addition, HES staining confirmed changes in cell density, which ultimately 
confirmed that increased ADC could be attributed to treatment-induced changes in the 
cellularity of the tumors and not, for example, altered perfusion.  
Overall, verification of histological causes for changes in ADC is challenging but 
necessary to bring the use of ADC as a biomarker further towards clinical application.  
 
5.1.3 Validating in vivo cell targeting kinetics by in vitro cell targeting experiments 
In paper III, DCE-MRI was used to investigate the spatial distribution of nanoemulsions 
in ovarian xenografts over time and to potentially estimate particle binding to Įvȕ3 
integrin. Conventionally, nanoparticle kinetics are studied in vitro by high resolution 
Discussion 
___________________________________________________________________ 
46 
 
methods such as fluorescent microscopy [117], but in this study the advantage of whole 
tumor coverage by DCE-MRI was exploited. This study was one of the first to use 
DCE-MRI to look at nanoparticle kinetics, which makes validation of the results 
especially necessary. One of the main results from the DCE-MRI was that the RGD 
targeted nanoemulsion showed a periodicity in its accumulation in the angiogenic tumor 
rim. It was hypothesized that this periodicity was caused by internalization of the 
nanoemulsion into endothelial cells after binding to Įvȕ3 integrin. To test this 
hypothesis, the distribution of the multifunctional nanoemulsion was visualized in 
histological tumor sections by fluorescent microscopy. This showed no clear evidence 
that the targeted nanoemulsion was internalized by the cells, which may be a result of 
the tissue handling during histology, in which the washing steps may cause the particles 
to be removed from the tissue. Therefore, an attempt was made to reproduce the 
periodicity in vitro. Although this was not an imaging experiment, the in vitro work 
confirmed a periodicity in the internalization of targeted nanoemulsion into HUVEC 
cells. Finally, Hak et al. showed earlier with IVM that the targeted nanoemulsion was 
located in close proximity to endothelial cell nuclei, which suggests that the 
nanoemulsion was internalized into the cells [117]. In this case of whole tumor imaging 
of nanoemulsion kinetics, no other available imaging modality could easily confirm the 
DCE-MRI results in the ovarian tumor xenografts because optical imaging such as IVM 
can only be performed using special setups such as window chambers, which can only 
accommodate thin tumors and could change other tumor properties. Also histology may 
not be the method of choice for looking at nanoparticle accumulation in tissue post 
mortem. Therefore, validation had to be performed in experimental setups not using 
whole ovarian xenografts. 
Paper III was one of the first studies to use and attempt to validate the use of DCE-MRI 
for monitoring in vivo targeting kinetics of nanoparticles to Įvȕ3 integrin. The 
experiments will have to be reproduced and further validated before DCE-MRI can be 
considered as a modality for studying nanoparticle kinetics and receptor dynamics.   
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5.2 Multi-modal imaging of tumor vessel morphology and function 
Blood vessels are essential for delivering nutrients and oxygen to drive tumor growth, 
and angiogenesis is one of the hallmarks of cancer. Imaging of tumor vasculature is 
important for several reasons. First, it can aid the understanding of angiogenic processes 
and guide the development of new anti-angiogenic drugs. Further, it can be used for 
tumor detection due to differences between tumor and normal vasculature. And third, it 
can be used for monitoring of anti-angiogenic therapy and for early detection of drug 
resistance.   
Blood vessels have a large range of sizes with the smallest capillaries having diameters 
of only 4m [98]. There are currently no in vivo imaging modalities that can accurately 
visualize a large volume of tissue with its blood vessels at such high resolution. In 
addition, tumor vasculature differs from normal vasculature in structure and function, 
and there is no single imaging modality that can simultaneously measure both 3D 
vascular architecture and vascular function in a whole tumor. Therefore, the use of 
multiple imaging modalities is commonly employed for studies assessing tumor 
angiogenesis.  
Imaging of the tumor vasculature was the main or a large part of all three papers in this 
thesis. Collectively, six imaging modalities were used to study tumor vasculature as 
summarized in Table 3. This table also summarizes the advantages and disadvantages 
of each imaging modality for vascular imaging, as encountered in the three studies.    
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Table 3: Summary of imaging methods used for characterizing tumor vasculature in this thesis. 
 Imaging 
Modality 
Use in papers Result Advantages (+) & 
Disadvantages (-) 
reso-
lution 
  
Histology 
visualization of 
cell nuclei (DAPI 
stain), endothelial  
cells (CD-31 
stain) and 
nanoemulsion 
(containing 
fluorescent dye)  
Results indicate that targeted 
nanoemulsion was located closely 
to the endothelial cells while 
control nanoemulsion extravasated 
into extravascular space. However, 
this was not clearly visible. 
Visualization was potentially 
hampered by histology processing 
steps. 
+ Possible to co-stain the tissue 
section with other markers 
+ Ex vivo technique that can be 
combined with in vivo imaging 
modalities 
- Ex vivo staining of vessels cannot 
differentiate between functional 
and dysfunctional vessels 
- no full tumor coverage 
  m 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8m 
 
 
 
 
 
 
 
 
 
 
40m 
 
 
 
 
 
 
 
 
 
0.1mm 
 
 
 
 
 
 
 
 
0.36 mm 
0.45mm 
 
 
 
 
 
 
 
 mm 
  
CLSM 
measurement of 
vascular input 
function that was 
used for DCE-
MRI modelling 
Using IVM, the fluorescent 
intensity in blood vessels could be 
measured over time after injection 
of fluorescent nanoemulsion. The 
data was converted into a Gd 
concen-tration/time curve and 
could be used as VIF for DCE-
MRI.  
+ Allows real time observation of 
fluorescent contrast agent kinetics 
in vasculature and surrounding 
cells  
+ Quantification of fluorescent 
intensity in blood vessels is 
possible 
- Not usable for large 3D tumors 
  
CT 
3D Angiography 
at 8m resolution 
in breast and 
ovarian tumor 
xenografts 
In paper I, the vasculature was co-
registered to in vivo MRI and 
served as ‘gold standard’ in the 
comparison of CT and SSC-MRI-
derived FBV. 
 
In paper II, FBV, vessel density, 
vessel radius and branch length 
were computed. No differences 
could be found between TOV-21G 
and TOV-112D and treated and 
control xenografts. 
+ High resolution, 3D volumetric 
imaging of blood vessels 
+ Whole-tumor coverage without 
sample sectioning  
- Successful contrast agent 
perfusion is necessary but can be 
complicated e.g. in case of 
dysfunctional vessels 
- Vessel segmentation from 
images can be challenging 
  
MRI 
three uses: 
1) imaging of 
vasculature at ~ 
40 m isotropic 
resolution 
2) co-registration 
3) soft tissue 
imaging for 
masking tumor 
from CT data   
In paper I, MRI visualized tumor 
vasculature at 40m resolution. It 
aided in the co-registration of CT 
and in vivo MRI data due to 
intermediate resolution and 
visualization of both vessels and 
soft tissue. 
  
In paper II, MRI was used to 
create a tumor mask for the CT 
data to distinguish between intra- 
and peritumoral blood vessels.   
+ Excellent soft tissue contrast 
distinguishes tumor tissue from 
normal tissue 
+ Whole-tumor coverage without 
sample sectioning 
+ Simultaneous imaging of vessels 
and soft tissue 
- Long data acquisition times 
- Resolution is not sufficient to 
resolve small capillaries; CT is 
therefore preferable for pure 
vascular imaging 
  
SSC-MRI 
Voxelwise 
computation of 
pre and post 
contrast R2* in 
breast xenografts; 
computation of 
FBV using 
equation (1.11) 
FBV values were overestimated by 
SSC-MRI compared to CT, but 
the distribution of FBV was similar 
for both modalities.  
SSC-MRI was able to visualize 
higher FBV in tumor rim compared 
to tumor center.  
+ In addition to FBV, computation 
of vessel size and density possible 
- Model-based computation of 
absolute FBV requires knowledge 
of ǻȤ 
+ In vivo imaging modality  
+ Repeated measurements 
possible 
+ Can be used in humans 
+ Can be combined e.g. with 
anatomical imaging 
+/- Sensitive to perfused blood 
vessels only 
  
DCE-MRI 
In paper II, 
vascular function 
was assessed 
using RSI, AUC, 
FEV and 
parameters 
based on the 
Tofts-model 
(Ktrans, ve, vp). 
 
In paper III, DCE-
MRI was used to 
visualize the 
kinetics of 
nanoemulsions 
containing Gd 
contrast agent. 
In paper II, RSI, AUC, FEV and ve 
rose significantly in both BEZ235-
treated ovarian tumor xenograft 
models compared to the control 
xenografts. 
 
In paper III, DCE-MRI visualized 
accumulation of RGD targeted 
nanoemulsion mainly in the tumor 
rim while the control nanoemulsion 
reached the central tumor to a 
larger extend. In the tumor rim, the 
targeted nanoemulsion 
accumulated faster than the 
control nanoemulsion and showed 
a periodicity in the accumulation, 
which may be attributed to 
receptor binding and recycling 
kinetics.  
+ Assessment of vascular function 
-Parameters are not easily 
interpretable, e.g. Ktrans depends 
both on vessel permeability and 
perfusion 
- Vascular parameters Ktrans, ve 
and vp are based on tracer-kinetic 
models  
- VIF required for computation of 
model-based parameters; 
acquisition of a suitable VIF can be 
challenging 
Pa
pe
r I
II 
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r I
II 
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5.2.1 Imaging of vascular morphology  
In paper I, three imaging modalities were compared in their ability to visualize tumor 
vascularization and measure tumor FBV. Of these modalities, CT can be regarded as 
the best modality to directly portray the tumor vasculature. In subsequent papers, CT 
of breast tumors was also used to characterize the vascular differences in tumors grown 
for 3 vs. 5 weeks [121] and to simulate tumor blood flow using bioimage informatics 
approaches [126]. In these studies, CT was regarded as the ‘gold standard’ although 
the resolution of 8 m was not sufficient to visualize the smallest capillaries. Still, other 
studies use even lower resolutions to study tumor vascularization [103] and vascular 
response to treatment [102]. In another recent study that also used Microfil as a contrast 
agent, CT was performed at resolutions down to 3.4 m and vessel diameters 
correlated excellently with histology [127].  With improvements in CT scanner 
hardware, CT at such high resolution will probably be more widely used in studies of 
angiogenesis.  
In paper I, MRI was also used to image the tumor vasculature ex vivo. While this 
method has the advantage that the soft tissue contrast can provide useful complementary 
data, it lacks the high resolution of CT, which resulted in an overestimation of the 
FBV due to partial volume effects. In addition, MRI at high resolution is very time 
consuming, which makes this method suboptimal for the sole purpose of imaging tumor 
vasculature.  While MRI is inferior to CT with regard to vascular imaging, it has 
helped in paper II to distinguish tumor vessels from peritumoral vessels (Fig. 10). 
  
Figure 10: High resolution ђMRI 
data (grey) overlaid with ђCT 
derived vasculature. The tumor 
vasculature is color coded in 
green/blue and the peritumoral 
vasculature in orange. 
 
 
As already explained in chapter 5.1.1, SSC-MRI was compared to the CT data, and it 
was shown that the FBV distributions were similar. While SSC-MRI is not routinely 
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used in the clinic, it has been used in clinical trials. To mention a few applications, FBV 
has been shown to correlate with tumor grade in human gliomas [128,129] and vessel 
size has been shown to decrease in gliomas as early as one day after treatment with 
cediranib [130].  
Overall, the results in this thesis in comparison with other studies suggest that CT is an 
excellent and unique method for visualizing the 3D tumor vasculature ex vivo, while 
SSC-MRI is a promising method for studying vascular morphology in vivo.  
 
5.2.2 Imaging of in vivo nanoparticle distribution in tumors using DCE-MRI and 
IVM 
There is an increasing amount of research being performed for the development of 
nanoparticles that can be used for targeted delivery of cancer therapeutics and for cancer 
diagnostic purposes. Such nanoparticles often contain contrast agents to facilitate the 
observation of their distribution in vivo. Appropriate contrast agents permit the 
visualization of nanoparticles e.g. using fluorescent imaging with IVM [117], whole 
body or tumor near infrared fluorescent imaging [131,132], nuclear imaging [133], CT 
[134] or MRI [135]. Among these imaging modalities, MRI has the advantages of 
providing whole tumor coverage and simultaneous anatomical imaging. Conventionally, 
MRI has been used to assess relative nanoparticle concentration in the tissue at set time 
points after administration. In the case of targeted nanoparticles, this helps to assess the 
relative concentration and distribution of the target sites. However, quantification of 
nanoparticle accumulation rates or targeting kinetics require repeated imaging with a 
temporal resolution suitable for description of ligand binding kinetics [117]. 
In paper III, an interesting multi-modality approach for studying nanoparticle kinetics 
was developed and its potential use to study vascular endothelial cell receptor dynamics 
was demonstrated. The multi-functional nanoemulsion, RGD-targeted or non-targeted 
control, was previously characterized and strong indications of cellular uptake of the 
RGD-targeted nanoemulsion were found [117]. In paper III, DCE-MRI revealed 
differences in accumulation rates for targeted and control nanoemulsion, i.e. the targeted 
nanoemulsion accumulated rapidly in the tumor rim, while the control nanoemulsion 
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accumulated more evenly throughout the tumor. The faster accumulation of the targeted 
nanoemulsion was observed previously by IVM [117], and the preferential targeting in 
the tumor rim has also been detected before and may be caused by the higher 
angiogenic activity in the tumor rim [132]. The MR images were acquired at a spatial 
resolution of 0.45 × 0.45 × 1 mm3 and a temporal resolution of 21.6 s. This relatively 
high temporal resolution permitted the quantification of the nanoemulsion targeting 
rates. With population-based VIFs, which were acquired by IVM for targeted and 
control nanoemulsion, the signal enhancement curves from the tumor rim were analyzed 
using the extended Tofts model. The estimated parameter Ki was about 10 times higher 
for the RGD nanoemulsion and ve was smaller, which again suggests that the RGD 
nanoemulsion accumulated faster and, additionally, more closely to the vasculature 
without diffusing far into the EES.  
Interestingly, the high temporal resolution permitted the observation of a periodicity in 
the enhancement curve of the targeted nanoemulsion. It was hypothesized that this 
periodicity originates from the receptor binding-internalization-recycling kinetics, 
which seems plausible as the period of the curve was in accordance with the range of 
the recycling half-lives of Įvȕ3 integrin [28]. In a study by Oostendorp et al., Gd-
containing nanoparticles were targeted to the CD13 receptor on endothelial cells, and 
the enhancement curves also suggested a periodicity in the accumulation of these 
targeted nanoparticles [136]. Although this study and our in vitro experiments supported 
the hypothesis that this periodicity is caused by receptor kinetics, the results remain to 
be reproduced and validated by further experiments.  
Though dynamic MRI is not commonly used to assess nanoparticle kinetics in tumors, 
several other studies have used it to study the kinetics of different targeted 
nanoparticles. Pharmacokinetic modelling was also used in these studies and showed 
differences between targeted and control nanoparticles [136-138]. Collectively, dynamic 
MRI has the potential to become a unique molecular imaging tool for quantification of 
nanoparticle accumulation rates and estimation of cell receptor expression and receptor 
dynamics on the whole tumor level. Thereby it may also be used in the design and 
optimization of nanoparticles and to study drug delivery to tumors.  
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5.2.3 Imaging of vascular function 
In paper II, vascular function was assessed using DCE-MRI, which is a method used 
both preclinically and clinically. Several parameters, i.e. AUC1min, RSI1min and FEV1min 
were derived directly from the enhancement curves.  while the parameters Ktrans, ve and 
vp were derived using the Tofts model. Ktrans is a frequently reported parameter for 
assessing vascular targeted therapies, but for low-molecular contrast agents such as 
Omniscan, which is approved for clinical use and was used in study II, this parameter is 
dependent on capillary permeability, vessel surface area, interstitial fluid pressure and 
convection, as well as the blood flow in the tissue. Therefore, it is difficult to ascertain 
the origin of any observed changes in Ktrans. Interestingly, in paper II, the non-model 
based parameters found that PI3K/mTor inhibition changed the tumor vasculature 
significantly, while the model based parameters found no significant changes. The lack 
of changes in the model based parameters could be attributed violation of model 
assumptions. One other challenge for quantifying DCE-MRI parameters using model-
based approaches is the necessity of a VIF, which should preferably be measured for 
each patient. However, it has been shown that there can be a high correlation between 
DCE-MRI parameters computed with individual and population-based VIFs [139]. 
Therefore, in papers II and III, population based VIFs were used for the data modelling.  
Since non-model based parameters are easy to acquire, they should be assessed in trials 
to determine whether they are more useful for response assessment than model-based 
parameters. However, these parameters can depend on acquisition details, which should 
be taken into account when comparing results acquired at different MR systems or using 
different sequences.  
Despite the mentioned drawbacks, DCE-MRI still has advantages over other methods 
assessing vascular function in vivo. DCE-MRI is non-invasive (except for the injection 
of Gd-containing contrast agents, which in rare cases can cause adverse reactions to 
Gd), has relatively high resolution, and can easily be combined with other MR imaging 
sequences.  
Other methods for characterizing vascular function are contrast enhanced ultrasound , 
Doppler ultrasound, DCE-CT or histological analysis following the in vivo injection of 
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dyes that stain perfused vessels or permeate into the EES and can thereby be used to 
estimate vessel permeability. To describe the advantages and disadvantages of these 
imaging modalities is beyond the scope of this thesis, but some of these methods are 
referred to in chapter 5.3.2.  
 
5.3 Multimodal imaging of drug response 
The traditional treatment of cancer, besides surgery, are chemotherapy or radiotherapy. 
When effective, these therapies lead to a reduction in tumor volume, which is usually 
assessed using MRI or CT or, where applicable, palpation. The newer generation of 
drugs, such as angiogenesis inhibitors and STIs are often regarded as cytostatic and 
rather change tumor vasculature, cellularity or cellular metabolism and proliferation 
before a decrease in tumor volume is measurable [47,82]. In addition, response can be 
spatially heterogeneous [140].Therefore, better methods are required, that can 
distinguish between the various forms of treatment response and multi-modal imaging is 
useful if each modality gives complementary information about the type of response. 
In paper II, the PI3K/mTor inhibitor BEZ235 was used to treat mice with ovarian tumor 
xenografts. Measurement of p-Akt after treatment indicated that xenografts grown from 
TOV-21G responded strongly to BEZ235, whereas the treatment had minimal impact 
on signal transduction in xenografts derived from TOV-112D. In the paper, multi-modal 
MRI was used to assess both the cellular and the vascular response in these two 
xenograft models.  
 
5.3.1 Cellular response to PI3K/mTor inhibition 
PI3K/mTor inhibitors like BEZ235 are STIs that are regarded as cytostatic, and it is 
frequently suggested that either vascular changes should be measured by DCE-MRI 
[141,142] or the metabolic response of the tumor cells should be assessed e.g. by FDG-
PET [46,143] or hyperpolarized 13C-MRS [144]. Initial testing of BEZ235 did not show 
that the drug induced apoptosis in cancer cells [33], and DW-MRI has not been 
mentioned in the literature to be useful for assessing response to PI3K inhibitors. 
However, recent studies have found that BEZ235 can induce cell death either via 
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apoptosis [145-147] or autophagy [146,148]. In light of these mentioned studies, the 
effect of BEZ235 on tumor cells seems to be dependent on the type of cancer cells. In 
paper II, the effect of this drug on ovarian tumor xenografts was assessed by DW-MRI, 
and the TOV-21G tumors showed significantly increased ADC values at the post 
treatment imaging time point (3 days after start of treatment). This increase was of 
similar magnitude as in studies where ADC increased in patients responding to 
conventional chemotherapy [149-151] and therefore suggests that DW-MRI may be a 
suitable method for monitoring treatment response to PI3K/mTor inhibition.  
Also, response to other STIs has been explored with DW-MRI, e.g. response to a 
MEK1/2 inhibitor [152], a Jak1/2 inhibitor [153] and sunitinib [154]; all of these 
preclinical studies reported an increase in ADC after 3-4 days.  
In paper II, decreased tumor volume was observed at the time of DW-MRI acquisition, 
but ADC can only be a useful biomarker for treatment response if it can measure 
response earlier than conventional methods, which are based on tumor size 
measurements. It would therefore be necessary to investigate if changes in ADC are 
measurable before volumetric changes. Currently, there are no clear guidelines on the 
usage of DW-MRI for therapy monitoring in cancer.  Reproducibility of ADC values 
needs to be taken into account, and data acquisition parameters, e.g. b-values, need to be 
standardized. It also still remains to be established how changes in ADC can be used for 
clinical decision making [155]. 
Collectively, it can be suggested that DW-MRI should be considered to be incorporated 
into clinical trials of STIs. In addition, a standardization of ADC measurement and 
response criteria should be performed so that DW-MRI can be a more useful method for 
treatment response assessment.  
 
5.3.2 Imaging of changes in vascular function and morphology induced by PI3K 
inhibition  
In paper II, changes in vascular function were assessed with DCE-MRI and changes in 
morphology with CT. The challenges regarding the interpretation of DCE-MRI 
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parameters and some methodological challenges of CT were discussed in chapter 5.2.3 
and chapter 5.1.1, respectively. Here, the focus will be on challenges regarding 
treatment response, with PI3K targeting as an example.  
Anti-angiogenic therapy is associated with changes in tumor vasculature. VEGF-
blockers such as bevacizumab directly inhibit angiogenesis, but signal transduction 
inhibitors such as PI3K inhibitors can also affect angiogenesis [38,156]. In paper II, 
DCE-MRI was used to assess changes in vascular function and it was found that 
RSI1min, AUC1min and FEV1min increased significantly in both tumor models upon 
treatment. Also an increase in Ktrans was observed. Vascular morphology was assessed 
by CT, but no changes were found due to large intra-group variation. These results 
were compared to results from other studies in which PI3K or PI3K/mTor inhibitors 
were used. For example, Qayum et al. have investigated the effects of the PI3K/mTor 
inhibitor PI-103 on the vasculature of SQ20B head and neck carcinomas and FVB-
MMT-neu spontaneous mammary carcinomas [157]. While their dose was low enough 
to not alter tumor growth compared to the control groups, they measured vascular 
changes in the form of increased blood flow using 3D Doppler Ultrasound (US); 
increased perfused vascular density, increased branch length and reduced 
tortuosity using i.v. injections of anti-CD31; and enhanced diffusion of Hoechst from 
the vessels into the tumor tissue. Collectively, they interpreted these changes as 
“vascular normalization”. The same authors then investigated the delivery of 
doxorubicin into the same tumor models after treatment with the specific PI3KĮ/į 
inhibitor GDC-0941 and found increased doxorubicin delivery and, as in the previous 
study, increased blood flow with no effect on tumor growth [158]. Sampath et al. used 
a PI3K inhibitor (GNE-490) as well as a PI3K/mTor inhibitor (GDC-0980) at doses that 
slowed down tumor growth [102]. In contrast to the results reported by Qayum et al., 
Sampath et al. found “antivascular effects” such as reduced FBV (referred to as vessel 
density but equivalent to our definition of FBV) measured by CT and histology, 
increased vessel size and decreased vessel density but no change in FBV measured 
by susceptibility contrast MRI, decreased blood flow measured by DCE-US, and 
decreased Ktrans measured by DCE-MRI. In yet another study, the drug BEZ-235 was 
used by Schnell et al. in BN472 rat mammary carcinomas [142]. Similar to Sampath et 
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al., they found inhibited tumor growth and decreased Ktrans. In addition and in contrast 
to Qayum et al., they found decreased diffusion of Evans Blue out of the vessels, 
suggesting decreased permeability, while there was no change in vascular density 
measured after i.v. Dextran-FITC injection.  
By comparing these studies it becomes clear that the vascular response to drugs 
targeting the PI3K pathway can have various forms as both increases or decreases in 
various vascular parameters have been measured. The increase in Ktrans that was 
measured in paper II therefore suggests that the vascular changes were of a different 
kind than those measured by Schnell et al. [142] and Sampath et al. [102], which may 
have been caused by various factors such as cell lines or drug dosage.  
The lack of change in vascular morphology in paper II may have been the result of the 
large intragroup variations. Since CT is an ex vivo imaging method, it is not possible to 
measure changes in vascular morphology longitudinally in the same mouse. This is 
clearly a disadvantage over in vivo imaging modalities because baseline variations 
cannot be accounted for.  
Surprisingly, in the study by Sampath et al., FBV decrease was measured by CT but 
not by SSC-MRI, which indicates that the varying results could also arise when 
different imaging modalities are used to measure a specific parameter and care should 
be taken when results are interpreted. Hence, it may be advisable that multi modal 
imaging is performed routinely in preclinical studies investigating vascular response as 
in the abovementioned studies.  
 
5.3.3 Cellular versus vascular response 
Interestingly, in paper II only the TOV-21G cell line showed a strong cellular response 
in the form of decreased p-Akt, decreased tumor volume and increased ADC. The TOV-
112D xenografts did not show such a cellular response but still exhibited changes in 
vascular function similar to those seen in the TOV-21G xenografts.  
These results indicate that a change in vascular function may not be enough for a tumor 
to respond to treatment, and in this case, the DCE-MRI parameters may be regarded as 
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false positive biomarkers. This is an important finding, and it is important to report false 
positive as well as false negative biomarkers [159] because these biomarkers need to be 
robust in order to be introduced into clinical practice.  
Paper II suggests that ADC may be more sensitive to overall treatment response than 
DCE-MRI. In addition, DW-MRI has several advantages over DCE-MRI because it is a 
fast imaging procedure for which no contrast agent administration is required and 
calculating ADC requires only basic mathematical computations.  
In general a combination of DW-MRI and DCE-MRI may be optimal because both 
cellular and vascular changes can be important for the overall treatment outcome. Still, 
both DW-MRI and DCE-MRI have similar challenges when it comes to their use for 
treatment response assessment in clinical applications. Among these are that both 
methods require more standardized imaging and data analysis procedures [70,82]. In 
addition, the methods need to become more robust, measurement errors and 
repeatability of quantitative parameters must be established, and quantitative guidelines 
for when a change in the imaging biomarkers indicates a treatment response are needed 
[70,82,143]. 
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6 Conclusions and future perspectives 
This thesis demonstrates the wide array of potential applications of multi-modal 
imaging for preclinical and clinical cancer research. Especially in vivo MR imaging has 
proven to be versatile as it allows assessment of vascular morphology and function as 
well as other aspects of the tumor microenvironment. It may also be useful for 
investigating receptor dynamics.  
Being able to assess cell receptor dynamics in vivo on the whole tumor level may 
critically advance our understanding of cellular processes, which are usually studied in 
vitro under conditions that do not fully represent the complex tumor environment. We 
demonstrated that a combination of DCE-MRI and IVM can be used to show 
differences in accumulation rates of RGD-targeted or non-targeted nanoemulsions. In 
addition, in vitro experiments suggested that the periodicity observed in the 
accumulation of RGD-targeted nanoemulsions may be caused by receptor 
internalization and recycling dynamics. These were some of the first experiments 
leading to these conclusions and in the future, a thorough reproduction of the results and 
an expansion of the experiments with different cell lines and different receptor targeting 
is necessary to confirm the results. If the results can be confirmed, this imaging 
platform may become widely used in the field of molecular imaging.  
Imaging of vascular morphology is useful for understanding angiogenic processes and 
can help with the development of vascular targeting drugs. In this work we have 
demonstrated that CT is a powerful method for visualizing tumor vasculature in great 
detail. The availability of high quality and high resolution vascular structures is 
important for the field of computational biology. But also for preclinical cancer 
treatment studies the use of CT can provide important information on vascular 
parameters that are conventionally assessed by hot spot analysis in histological data. 
Since histology does not allow full coverage of tumors, CT may be considered a 
superior method in this context. For future studies it would be beneficial if the CT 
resolution would be below the smallest vessel size. As the CT-scanners are constantly 
improving, this is now just a matter of scanner accessibility and costs. Combination of 
morphological information obtained using CT with functional information obtained 
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using MRI would provide a comprehensive multimodal description of tumor 
vascularity, which would be useful for understanding effects of antiangiogenic drugs in 
more detail. 
For this thesis, three in vivo MR imaging modalities were used to characterize tumor 
xenografts, namely SSC-MRI, DCE-MRI and DW-MRI. For SSC-MRI we 
demonstrated that the FBV measurements were distributed similarly to those obtained 
by CT, but that the values were overestimated. SSC-MRI is not routinely used in the 
clinic and especially not often outside the brain. The limited availability of approved 
contrast agents may be a factor preventing it from being used more often. DCE-MRI 
and DW-MRI were used to assess tumor response to PI3K/mTor inhibition. 
Importantly, we have demonstrated that DW-MRI may be a suitable method for 
assessing tumor response to STIs even though these are mostly considered cytostatic. 
Follow-up studies are required to test if the ADC increase can also be measured before a 
decrease in tumor volume is measurable, which would be an advantage over 
conventional assessments of tumor burden. DCE-MRI showed a vascular response in 
both tumor models, which did not the differential cellular response of the two xenograft 
models. Therefore, vascular response may not necessarily be sufficient for a complete 
tumor response. 
The multi-modal imaging platforms presented in this thesis provide a fundament for 
further studies that could be performed to systematically compare imaging biomarkers 
for response to anti-angiogenic drugs as well as drugs targeting signal transduction 
pathways. Ultimately, it is desired that guidelines are improved and these biomarkers 
become so robust that they can aid clinical decision making. The validation of 
biomarkers reported in this thesis may contribute to a better understanding of how 
different imaging modalities reflect physiological changes in tumors after therapy. As 
demonstrated in this work, future therapy monitoring in cancer may depend on 
combinations of biomarkers rather than single markers. Understanding the individual 
contributions in multimodal imaging regimens in various contexts will be necessary to 
bring these methodologies into clinical practice. Progress in this field requires a 
continued mapping of cellular and vascular responses to treatment and continued 
development of methods for integration of data from multiple sources. 
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